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Abstract
Acute lower limb ischaemia (ALLI) is a condition that often requires urgent or emergent 
surgical or endovascular treatment. This disorder is associated with major amputations and 
mortality. The aetiopathogenesis of ALLI has changed within the last decades. Currently, 
it mainly presents with atherosclerosis-associated thrombotic occlusions. An increasing 
volume of data has been published in favour of a possible bacterial inflammation that 
can contribute to the pathogenesis of thrombotic events, particularly in patients with 
atherosclerotic changes. The patients who present with ALLI are often elderly individuals 
with multiple comorbidities. Therefore, mini-invasive treatment modalities are preferred. 
Nonetheless, catheter-directed thrombolysis occasionally fails and leads to amputations. 
Even after successful fibrinolysis, some patients develop recurrent ischaemia and require 
new interventions. 
The aim of this work was to study the possible aetiological issues related to ALLI from 
the viewpoint of bacterial deoxyribonucleic acid (DNA) presence in the thrombi. Further 
aims were to evaluate possible reasons behind thrombolytic treatment failure and recurrent 
ALLI, and to assess the long-term outcome of thrombolytic treatment.
The thrombus aspirates were obtained aseptically and examined for the presence of 
bacterial DNA with a quantitative polymerase chain reaction from September 2014 to 
October 2016. A retrospective analysis of the ALLI patients treated at Tampere and Turku 
University Hospitals from January 2002 to December 2015 was performed to address the 
other aforementioned questions. 
A total of 303 cases of ALLI (159 men [52.5%]) were registered in the studies. The 
mean age of the patients was 71 years. A total of 58% of the native arterial and 75% of the 
bypass graft thrombi were identified as positive for bacterial DNA. Synthetic graft thrombi 
demonstrated positivity for bacterial DNA in 77.8% of the cases. Of the positive samples, 
90% contained the Streptococcus mitis group DNA. 
In patients managed with thrombolysis, an early treatment failure occurred in 23%. A 
delay in treatment initiation increased the risk of failure by 5% per day. Hyperlipidaemia 
and previous bypass grafting were also independently associated with failure. This 
resulted in an almost 40% risk of major amputations within the first month. Nearly 43% 
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of the patients developed recurrent ischaemia within a median of 40 months. Bypass 
graft reocclusions were predominant (65%). The absence of appropriate antiplatelet or 
anticoagulant treatment in native arteries and worsened tibial runoff in bypass grafts were 
independently associated with the risk of recurrent ALLI. 
At one year, almost 80% of the patients were alive. The primary patency rate at this 
point for native arteries was 87%. The primary patency rates for bypass grafts ranged from 
31% to 62%, with the lowest rates found in autologous vein grafts. The amputation-free 
survival rate was 66%. 
The long-term outcomes were unfavourable. At five and ten years, 56% and approximately 
30% of the patients, respectively, were alive. The survival was independently associated with 
the presence of atrial fibrillation and an age of over 83 years. The 10-year primary patency 
rates for native arteries and conduits were 18.7% and 15.2%, respectively. The amputation-
free survival was independently affected by an age of over 75 years and represented a rate of 
24% at 10 years. 
The information on the presence of bacterial DNA in the thrombi must be interpreted 
with caution. Additional studies are needed to establish whether these findings are 
involved in the actual thrombotic process. The short-term post-thrombolytic outcomes 
are superior to the long-term outcomes, which are poor. Recurrent ischaemia is frequent 
and affects the results. Both modifiable and non-modifiable factors have an impact on 
the treatment outcome. They should be taken into consideration in the clinical work and 
further investigations. 
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Tiivistelmä
Akuutti alaraajaiskemia (AAI) on tilanne, joka vaati kiireellistä tai välitöntä kirurgista tai 
suonensisäistä hoitoa, ja on yhteydessä lisääntyneeseen amputaatio- ja kuoleman riskiin. 
AAI:n etiopatogeneesi on muuttunut viime vuosikymmenien aikana. Nykyään suurin 
osa iskemiasta johtuu ateroskleroosin aiheuttamista valtimoahtaumista. Viimeaikaiset 
tutkimukset ovat osoittaneet, että bakteeritulehdus saattaa vaikuttaa tromboosiin, 
varsinkin potilailla, joilla on ateroskleroottisia muutoksia. AAI-potilaat ovat usein 
iäkkäitä ja monisairaita, jolloin liuotushoitoa pidetään hyvänä vaihtoehtona avokirurgialle. 
Siitä huolimatta katetriohjattu trombolyysi saattaa epäonnistua, ja tämä voi liittyä 
lisääntyneisiin amputaatioihin. Onnistuneenkin liuotushoidon jälkeen joillekin potilaille 
kehittyy uusintaiskemia, johon liittyy uusintatoimenpiteitä. Hoidon pitkäaikaistulokset 
AAI-potilailla jäävät usein epäselviksi.
Väitöstutkimuksen aiheena oli selvittää AAI:n taustatekijöitä mukaan lukien uusia 
etiologisia tekijöitä, hoidon pitkäaikaistuloksia ja niihin vaikuttavia tekijöitä. 
Tutkimuksen retrospektiivisissa töissä aineistona käytettiin Tampereen ja Turun 
yliopistollisissa sairaaloissa hoidettujen potilaiden tietoja. Prospektiivisessa osiossa 
kerättiin AAI-potilaiden trombiaspiraatteja bakteeri-DNA:n tunnistamiseksi. 
Yhteensä 303 AAI-tapausta (159 miestä [52,5 %]) rekisteröitiin tutkimuksiin. 
Potilaiden keski-ikä oli 71 vuotta. Lähes 60 % natiivivaltimoista ja 75 % ohitteista 
olivat bakteeri-DNA-positiivisia. Synteettiset ohitteet olivat positiivisia lähes 80 %:lla 
potilaista. Kaikista positiivisista valtimonäytteistä 90 % sisälsi Streptococus mitis ryhmän 
DNA:ta. Trombolyysillä hoidetuilla potilailla varhainen hoidon epäonnistuminen oli 
todettavissa 23 %:ssa tapauksista. Hyperkolesterolemia, aikaisempi ohituskirurgia ja 
hoidon aloituksen viivästyminen liittyivät itsenäisinä tekijöinä epäonnistumiseen, joka 
oli yhteydessä melkein 40 %:n amputaatioriskiin ensimmäisen kuukauden kuluessa. 
Uusintaiskemia ilmaantui melkein 43 %:lle potilaista 40 kk:n mediaaniseurannan aikana. 
Ohitteiden uusintatukoksia esiintyi merkitsevästi useammin natiivivaltimotapahtumiin 
verrattuna. Asianmukaisen verenohennus- tai antiaggregatorisen lääkityksen puute 
sekä säärivaltimoiden ulosvirtauksen heikkous ennustivat itsenäisesti uusintaiskemian 
kehittymistä.
xYhden vuoden kohdalla lähes 80 % potilaista oli elossa. Primaarinen aukipysyvyys 
natiivivaltimoissa oli 87 %. Ohitteiden aukipysyvyys tällä ajankohdalla oli 31 %–62  %. 
Amputaatiovapaa  elossaolo oli 66 %. Pitkäaikaistulokset olivat epäsuotuisia. Kymmenen 
vuoden kohdalla noin 30 % potilaista oli elossa. Eteisvärinä ja korkea ikä (yli 83 
vuotta) ennustivat itsenäisesti huonoa eloonjäämistä. Primaarinen aukipysyvyys oli 
natiivivaltimoissa 18,7 % ja ohitteissa 15,2 %. Yli 75 vuoden ikä vaikutti itsenäisesti 
amputaatiovapaaseen elossaoloon ollen 24 % kymmenen vuoden kohdalla. 
Huolimatta siitä, että bakteereiden DNA:ta löydettiin trombiaspiraateista, tietoon 
täytyisi suhtautua varovaisesti, sillä syy-yhteyksien osoittaminen vaatii lisätutkimuksia. 
Katetriohjatun trombolyysin tulokset lyhyellä aikavälillä ovat pitkäaikaistuloksia 
paremmat. Uusintatapahtumat ovat yleisiä, ja pitkäaikaisennuste on epäsuotuisa. Vain 
osaan hoidon tuloksiin vaikuttavista tekijöistä voidaan vaikuttaa. Nämä tekijät tulisi 
huomioida sekä kliinisessä työssä että tulevissa tutkimuksissa.
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1 Introduction
Acute lower limb ischaemia is a condition caused by a sudden restriction of blood circulation 
in tissues lasting 14 days or less (Gilliland et al. 2017). It results in a lack of oxygen and 
nutrient supply to the affected limb and may potentially threaten the viability of the lower 
extremity. 
Despite the relatively high technical success rate of the thrombolytic treatment that 
exceeds 70% (Acar et al. 2013), the early amputation rates remain high. They range from 
10% to 30% in the short term (Byrne et al. 2014; Koraen et al. 2011; Norgren et al. 2007) . 
The reasons for this could be partially explained by treatment failure, along with underlying 
comorbid conditions. The threat, however, is not only limited to the viability of the limb. 
These patients are at a high risk of mortality (Van Damme et al. 2018). 
The effective treatment of rheumatic heart disease (RHD) and endocarditis in 
particular has reduced the incidence of embolic events (O’Connell & Quiñones-Baldrich 
2009). With the ageing population (Van Damme et al. 2018), the prevalence of peripheral 
arterial disease (PAD) has, however, increased (Criqui & Aboyans 2015). Diabetes, chronic 
renal insufficiency, smoking and hypertension are significantly associated with PAD 
and increase the likelihood of its presence (Eraso et al. 2014). Therefore, more complex 
conditions may turn ALLI into a multidisciplinary situation. The circulation restriction 
in such circumstances leads to systemic electrolyte abnormalities that impair the renal 
and cardiopulmonary functions. Furthermore, a sudden successful reperfusion may, in 
some cases, worsen the patient’s condition, owing to the release of toxic substances into 
the circulation. Whether the patient is in the end-of-life stage and whether an invasive 
approach should still be undertaken can often pose a clinical challenge.
Recent investigations have suggested the possible role of bacterial inflammation in the 
aetiology and pathogenesis of cardiovascular diseases (Pessi et al. 2013; Pyysalo et al. 2016; 
Renko et al. 2013) . The presence and role of such microorganisms in the ALLI setting have 
not been studied. The issue can appear relevant, since certain bacterial species are known 
18
for their ability to bind platelets (Bensing et al. 2001) and, possibly, contribute to thrombus 
formation. 
Despite innovations in science and engineering, as well as in diagnostic modalities and 
treatment, the morbidity and mortality after ALLI remain high (Van Damme et al. 2018). 
During the last decades, the aetiopathological characteristics of ALLI have been changing 
(Van Damme & Limet 2005), which makes it interesting to assess the problem from the 
viewpoints of possible bacterial involvement and factors that impact on treatment failure 
and affect the outcomes in the long term.
19
2 Review of the Literature
2.1 Epidemiology and aetiological aspects of 
acute lower limb ischaemia (ALLI)
The information on the incidence of acute lower limb ischaemia is insufficient. According 
to Dormandy and colleagues (1999), it is estimated to constitute 10%–16% of the vascular 
workload, with a reported incidence of 14 per 100,000 in the general population. The 
number of hospital admissions because of ALLI has decreased from 45.7 per 100,000 in the 
1990s to 26 per 100,000 in the 2000s, as reported by Baril and colleagues (2014). ALLI is 
equally distributed between women and men. This pathological condition mainly affects 
the older population with a median age of 75 years (Smith & Lilie 2019). The risk factors 
for ALLI include increasing age, smoking, diabetes mellitus and hypertension (Smith & 
Lilie 2019). 
Earlier, when RHD could not be properly managed, the condition was often 
complicated with the development of peripheral arterial thromboembolism. Alexander 
Fleming discovered penicillin in 1928 (Fleming 1929), but it took another 17 years for its 
mass production and distribution to be launched (Aminov 2010). Jay McLean at Johns 
Hopkins discovered unfractionated heparin in 1918 (introduced in clinical practice in 
1940s) (Franchini et al. 2016), and Karl Link synthesized warfarin in 1948 (in clinical 
practice in 1950s) (Pirmohamed 2006). In developed countries, these innovations have 
reduced the incidence and prevalence of RHD and subsequent embolism. Nevertheless, 
these conditions are still recognized as major causes of morbidity and mortality in 
developing nations, accounting for approximately 233,000 deaths annually (Carapetis et al. 
2005). With an ageing population, the presentation of ALLI due to thrombosis becomes 
more common and, in some series from the developed countries, exceeds 60% of all cases 
(Grip et al. 2014). 
20
2.2 Pathogenesis of ALLI
The main reasons of ALLI are thrombosis and embolism. Acute lower limb ischaemia 
may also occur as a result of trauma, dissections, iatrogenic injuries, entrapment or cysts, 
as well as a hypercoagulable state, aneurysm thrombosis and some other rare conditions 
related to a sudden restriction in limb perfusion (Acar et al. 2013). It is noteworthy that 
the differential diagnosis of these causes may be difficult. Even after a thorough clinical 
examination, the distinction between the two entities can be challenging, “since ischaemia 
can be the consequence of arterial embolism in a diseased atherosclerotic artery” (Van 
Damme & Limet 2005).
2.2.1 Embolism
The word “embolus” comes from Greek and means “a plug”. An embolus usually refers to a 
blood clot or sometimes an air bubble, pieces of adipose or atherosclerotic tissues that are 
spread through the blood stream and result in blood vessel occlusion or stenosis. Arterial 
thromboembolism predominantly occurs owing to cardiac reasons, with atrial fibrillation 
as the most frequent one (Lyaker et al. 2013), causing approximately 67% of all embolic 
events (Van Damme & Limet 2005). Myocardial infarction is less common (12%), while 
rheumatic valvulopathy (3%) and prosthetic valve-related emboli (2%) are the least probable 
cardiac reasons of embolism (Van Damme & Limet 2005). According to the same author, 
other embolic sources would include artery-originated emboli (5%), paradoxical emboli 
from the venous system that pass through a patent foramen ovale into the arterial system 
(1%), and emboli of an unknown origin (10%). Emboli usually travel through the large-
diameter vessels unimpeded and naturally occlude smaller peripheral arteries. Although 
large-sized emboli may lodge in the aortic bifurcation, the most commonly affected part 
of the body is the lower limb (Abbott et al. 1982), with the occlusions found in the femoral 
bifurcation in over a half of the cases (Table 1) (Van Damme & Limet 2005). 
???????????????????????????????????????? ????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????
Sart Tilman, 4000 Liège, Belgique (Van Damme & Limet 2005)
Anatomical location Incidence (%)
Aorto-iliac segment 8%
Iliac bifurcation 12%
Femoral bifurcation 55%
Popliteal artery 20%
Tibial artery 5%
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Patients presenting with embolic events usually have healthy arteries and insufficient 
collateral circulation (Figure 1). Once the blood supply to the extremity through an 
occluded vessel is interrupted, the patient presents with an acute pain and sensorimotor 
deficit. The clinical situation may worsen due to the development of secondary thrombotic 
occlusions both proximally and distally to the embolic obstruction. 
Due to the achievements in medicine and to more efficient treatment of RHD, 
endocarditis and congenital heart conditions (O’Connell & Quiñones-Baldrich 2009), the 
incidence of embolism has decreased over time (Figure 2) (Van Damme & Limet 2005). 
Figure 1. A schematic illustration of 
embolism (left) and thrombosis in situ 
(right). ©Damir Vakhitov
Figure 2. The evolution of the 
causes of acute lower limb arterial 
obstructions over time. The x 
axis demonstrates years and the 
y axis percentages. The black 
curve represents embolism and 
the dashed curve thrombosis. 
?????????????????????????????????
by Dr. H. Van Damme. Service 
de Chirurgie Cardiovasculaire et 
???????????????????????? ????
4000 Liège, Belgique (Van 
Damme & Limet 2005)
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2.2.2 Thrombosis
Conversely, the incidence of arterial and bypass graft thrombosis has increased over time 
(Van Damme & Limet 2005) and currently outnumbers that of embolic events (Grip et 
al. 2017). The progression of underlying atherosclerosis and subsequent development 
of an arterial stenosis or occlusion may predispose PAD patients to thrombotic events. 
Furthermore, aneurysms, hypotension, hypercoagulable states and hypovolaemia can also 
contribute to the pathogenesis of thrombosis. Additionally, trauma, arterial dissections 
and malignancy may also play a potential role in the development of thrombotic occlusions 
(O’Connell & Quiñones-Baldrich 2009). 
Various reasons lead to platelet aggregation and subsequent thrombosis in situ. A 
critical atherosclerotic narrowing of the arterial lumen is one of them. These patients often 
have a history of chronic ischaemia (e.g. claudication). However, an acute onset of the 
symptoms is also possible. Generally, within several hours from the onset, some patients 
may experience symptom relief due to the “opening” of collaterals. Another possible reason 
is an atherosclerotic plaque rupture, also believed to induce thrombosis (Earnshaw 2001). 
The mechanisms are not completely understood. In the coronary vessels, however, a chronic 
low-grade bacterial inflammation could contribute to these processes (Pessi et al. 2013). 
Interestingly, such bacteria are found in the oral cavity and could be haematogenically 
spread to the plaque especially after dental procedures (Pessi et al. 2013).
Hypercoagulable states may develop as a result of congenital or acquired disorders (Khan 
& Dickerman 2006). Among these are thrombophilias of different types, such as sticky 
platelet syndrome, antiphospholipid antibody syndrome, cancer-related hypercoagulability 
and a heparin-induced thrombocytopenia.
Arterial dissections often occur owing to trauma or systemic connective tissue disorders. 
As a result of mechanical obstruction, the blood supply to the limb is diminished, leading 
to thrombosis development.
2.2.3 Occlusions of bypass grafts
With the development of vascular services in developed countries, the incidence of bypass 
graft occlusions has increased and, in some populations, reached 15% (Campbell et al. 
1998). Bypass graft patients usually present with thrombosis rather than embolism. The 
management of these conditions is similar to that of native arterial acute limb ischaemia.
2.2.4 Contribution of bacteria to the thrombotic process
The initiation and progression of atherosclerotic lesions involves a chronic inflammatory 
response driven by oxidized low-density lipoprotein. It is characterized by an inability to 
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resolve the inflammation, leading to advanced atherosclerotic lesions (Virmani et al. 2005). 
The possibility that bacterial infections might directly or indirectly contribute to this 
process is still under investigation (Rosenfeld & Campbell 2011). The variety of bacterial 
species possibly involved in atherosclerotic plaque progression is wide. It comprises bacteria 
of the gastrointestinal tract, pulmonary micro-organisms, as well as pathogens of dental and 
periodontal origin (Olsen 2008; Rosenfeld & Campbell 2011). Mainly deoxyribonucleic 
acid (DNA) of the Streptococcus mitis group (S. mitis group) was revealed in thrombus 
aspirates from myocardial infarction patients (Pessi et al. 2013) or patients with cerebral 
aneurysms (Pyysalo et al. 2016; Pyysalo et al. 2013). These microorganisms inhabit the oral 
cavity but can also participate in the formation of dental biofilms that calcify into dental 
plaques. The streptococci are common agents in infective endocarditis and septicaemia 
(Kerrigan & Cox 2012). They possess the ability to bind platelets (Bensing et al. 2001) and 
adhere to an endothelial surface (Bensing et al. 2001; Leishman et al. 2010; Mitchell et al. 
2007), thus possibly participating in thrombosis.
???? ?????????????????????
ALLI can be classified in accordance with the aetiological factors – thrombosis or embolism. 
Unfortunately, whether an occlusion is an embolus or thrombus cannot always be proven 
definitively (Van Damme & Limet 2005). Besides, it has become clear that a classification 
based on the severity of ischaemic changes would be more valuable to determine the 
urgency of required treatment. 
The Society for Vascular Surgery and the International Society for Cardiovascular 
Surgery have established definitions based on the severity of ischaemia (Rutherford et al. 
1997). These standards were later altered by the Trans-Atlantic Inter-Society Consensus, 
according to which ALLI can be defined as a sudden decrease in limb perfusion, causing a 
potential threat to the viability of a limb (Norgren et al. 2007).
ALLI may be asymptomatic in the presence of well-developed collaterals. In their 
absence or insufficient presence, sensory loss, followed by a motor deficit, will develop and 
lead to muscle weakness and, finally, skin changes (Figures 3–5, Table 2).
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Figure 3. Category 
IIa ALLI (patient’s 
right leg). (Table 2). 
©Damir Vakhitov
Figure 4. Category IIb ALLI (patient’s right leg). (Table 2) 
©Damir Vakhitov
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Category Description/prognosis
Findings Doppler Signals
Sensory 
loss
Muscle 
weakness
Arterial Venous
I. Viable Not immediately threatened None None Audible Audible
II. Threatened
a. Marginally
b. Immediately
Salvageable if promptly treated
Salvageable with immediate 
revascularization
Minimal 
(toes) or 
none
More than 
toes, rest 
pain
None
Mild, 
moderate
Inaudible
Inaudible
Audible
Audible
III. Irreversible Major tissue loss or permanent 
nerve damage inevitable
Profound, 
anaesthetic
Profound, 
paralysis
Inaudible Inaudible
2.4 Diagnostic imaging
A clinical examination often provides a physician with the required information. 
Therefore, radiological examinations may not be routinely needed. Several options of 
diagnostic imaging are, nonetheless, available, if a prompt diagnosis cannot be made. The 
role of minimally or non-invasive methods is evolving. Digital subtraction angiography 
(DSA), however, remains the gold standard (Weiss et al. 2017). It is the only diagnostic 
modality that permits the simultaneous treatment of acute occlusions (Weiss et al. 2017). 
Figure 5. Category 
III ALLI. (Table 2) 
©Damir Vakhitov
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Nevertheless, conventional contrast angiography seems to be inferior in its accuracy in 
comparison with magnetic resonance angiography (MRI) (Lapeyre et al. 2005). 
The diagnostic performance of MRI in PAD patients is high, with a sensitivity of 
94.7% and a specificity of 95.6% (Menke 2010). In addition, the accuracy of MRI has been 
shown to be superior to that of computed tomography for examining below-the-knee 
vessels (Young et al. 2013). In a recent report (Varga-Szemes et al. 2017), non-contrast 
quiescent-interval single-shot magnetic resonance angiography provided high diagnostic 
accuracy in comparison with DSA in PAD patients. The authors suggested that such an 
imaging modality obviated the need for contrast administration. With the need for urgent 
diagnosis and intervention, the role of MRI in ALLI may, however, be limited (Fernando 
& Bakhos 2017).
The diagnostic performance of computed tomography angiography (CTA) is also 
high. The sensitivity and specificity of this method for detecting stenosis of over 50% are 
largely comparable to those of contrast-enhanced MRI. Nonetheless, a separate imaging 
technique for detecting lesions of a tibial segment by MRI is preferred (Jens et al. 2013). 
CTA is, however, widely used when MRI is unavailable, undesirable due to claustrophobia, 
or contraindicated (pacemaker, insulin pump, metallic foreign bodies, gastric reflux device 
and some others). 
Duplex ultrasonography is a non-invasive method, the diagnostic precision of which 
is, however, inferior to that of MRI, contrast angiography or CTA (Collins et al. 2007). 
Nevertheless, in expert hands, the method provides acceptable accuracy, particularly for 
the diagnostics of the above-the-knee arteries. 
2.5 Treatment of ALLI
2.5.1 Conservative treatment of ALLI
Anticoagulants have been administered to patients with ALLI for at least several decades. 
Blaisdell F. and colleagues (1978) suggested that high-dose heparin therapy could be 
helpful in conjunction with delayed interventions on ALLI patients. Anticoagulation helps 
to reduce or stop the propagation of thrombosis, to prevent new embolic events and to 
maintain collateral circulation. In their 2016 guidelines, the American Heart Association 
and the American College of Cardiology suggested systemic anticoagulation with heparin 
unless contraindicated (Gerhard-Herman et al. 2017). 
Berridge and colleagues studied the benefits of oxygenation in 1989. They found that 
“continuous oxygen inhalation during acute ischaemia may improve tissue nutrition 
before, during and after definitive treatment” (Berridge et al. 1989). Apart from that, there 
is currently no evidence that vasoactive drugs would be of clinical benefit to patients with 
ALLI. 
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It is obvious that the management of ALLI with anticoagulation alone may not be a 
durable option in most cases. This treatment modality is occasionally reserved for those 
with multiple severe comorbidities and of advanced age, when other definitive surgical or 
endovascular procedures cannot be offered and the patient’s life expectancy is otherwise 
short.
2.5.2 Modern surgical treatment
After 1961, when Thomas Fogarty introduced a balloon catheter for blood clot removal, 
surgical revascularization became the main option in acute limb ischaemia treatment 
(Figure 6). The procedure is relatively quick, and it can be performed under local anaesthesia. 
Despite the decrease in the incidence of embolic events over time, the limb salvage and 
post-operative survival rates have not improved (Ljungman et al. 1996). The life expectancy 
in developed countries during the last decades has increased, and the profile of ALLI has 
changed. The patients increasingly present with thrombosis (Van Damme & Limet 2005; 
Ljungman et al. 1996), which makes the management of such acute ischaemic conditions 
more complex. Additional open, endovascular or hybrid procedures that include both 
open and endovascular modalities are often needed to achieve adequate distal perfusion 
(Figure 7) (Byrne et al. 2014). The management of ALLI in hybrid operation suites could 
be recommended for that reason.
Figure 6. Small-sized emboli are removed from the tibial 
arteries with a Fogarty balloon catheter using the distal 
popliteal artery access. ©Damir Vakhitov
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2.5.3 Endovascular treatment
In 1933, W. Tillett and R. Garner at Johns Hopkins Medical School in Baltimore, MD, 
found certain strains of Streptococcus haemolyticus to be capable of the rapid dissolution of a 
normal human fibrin clot (Tillett 1933). The first clinical reports on the use of thrombolysis 
were also published in the USA and date back to the 1950s. At that time, the reports 
concerned acute coronary syndrome treatment with massive intravenous streptokinase 
therapy (Fletcher et al. 1958). The risk of haemorrhagic complications was high, since large 
amounts of thrombolytics were required. A significant step forward was taken with the 
introduction of intracoronary fibrinolytics administration. The pioneers of this innovation 
were E. Chazov in the Soviet Union and K. Rentrop in West Germany (Chazov et al. 1976; 
Rentrop et al. 1979). Years of experimental work resulted in improved treatment regimens, 
better instrumentation and lower peri-procedural risks. This allowed the method to be 
applied not only in the field of cardiology but also in the management of acute peripheral 
arterial occlusions of the upper and lower extremities. 
The modern endoluminal treatment of ALLI is based on the use of pharmacological 
intra-arterial thrombolysis with several technical variations. The method in its current form 
has been available for approximately 30 years. This modality offers relatively high technical 
success rates that exceed 70% (Byrne et al. 2014). In order to restore sufficient circulation 
and tissue perfusion, additional endovascular (balloon dilatation and stenting) or open 
procedures may be needed upon the completion of fibrinolytic therapy or, occasionally, 
within the treatment course. 
Mechanical aspiration thrombectomy could be considered alternatively. The potential 
advantage of this method is that the procedure can be followed by thrombolysis, if the 
??????????????????????????????????????????????????
artery treated by means of eversion endarterectomy. 
©Damir Vakhitov
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aspiration attempts fail. The available data on the use of aspiration thrombectomy in ALLI 
is, however, insufficient, and no definitive conclusions can be drawn at this point. According 
to the recent study from Australia (Kwok et al. 2018), which included 15 patients treated 
with aspiration thrombectomy and 27 patients treated with catheter-directed thrombolysis 
(CDT), the primary technical success rates were 53% versus 89%, respectively. The authors 
concluded that aspiration thrombectomy could reduce the need for CDT (Kwok et al. 
2018).
2.5.4 Amputation as a primary treatment option in ALLI
In general, major amputations are performed on patients with Class III ALLI when further 
revascularization is not an option due to irreversible and permanent ischaemic changes. 
Furthermore, amputations could be considered after failed revascularization attempts in 
patients with otherwise non-salvageable limbs or those in whom revascularization cannot 
be performed due to anatomic factors (Abou-Zamzam et al. 2003).
2.5.5 Open surgery versus thrombolysis
A comparison of CDT and conventional surgical modalities for the treatment of ALLI 
may appear questionable due to the diverse clinical presentations and a wide repertoire of 
surgical procedures used. Nevertheless, a number of randomized trials have succeeded in 
performing such an evaluation (The Stile Investigators 1994; Ouriel et al. 1994; Ouriel et 
al. 1996; Ouriel et al. 1998). The increased risk of ongoing ischaemia, bleeding and stroke 
was associated with CDT (Berridge et al. 2002). The studies, however, demonstrated no 
difference in limb salvage or death rates at thirty days, six months or one year (Berridge et 
al. 2002). A recent study from Sweden (Grip et al. 2018), which included over 6,700 patients 
after propensity score matching, concluded that, although the primary endovascular 
approach was equally effective as open surgery in regard to limb salvage, it was associated 
with reduced mortality rates at thirty days and after one year post-procedurally. 
2.6 Catheter-directed thrombolysis (CDT)
2.6.1 Thrombolytics
There are currently several types of thrombolytic agents that can be classified according to 
their generations (Ali et al. 2014) (Table 3).
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Generation of thrombolytic drugs Thrombolytic agent
First generation Streptokinaseurokinase
Second generation recombinant tissue plasminogen activator (tPA) -Alteplase
Third generation
Tenecteplase
Reteplase
Monteplase
Lanoteplase
Pamiteplase
Streptokinase was the first thrombolytic agent used in humans. The tissue plasminogen 
activator (tPA), however, seems to be safer and to offer lower systemic effects when 
administered as a low-dose intra-arterial infusion (Berridge et al. 1989). There is no strong 
evidence that tPA is more effective than urokinase. There is, however, evidence that the 
thrombolytic treatment might be more rapid with tPA (Robertson et al. 2013); see Table 4. 
Reteplase, a representative of third-generation thrombolytic drugs, is similar to tPA but has 
a longer half-life and superior penetration ability. Tenecteplase is also similar to Alteplase 
but with better binding affinity to fibrin and an even longer half-life than that of Reteplase 
(Karnabatidis et al. 2011); see Table 4. The reports on the use of these newer agents in ALLI 
are, however, few. According to the available data, the results of treatment with reteplase 
are acceptable and promising (Davidian et al. 2000), but a controlled comparison to other 
thrombolytic drugs is, however, needed before a definitive conclusion could me drawn 
(Ouriel et al. 2000).
???????????????? ????????????????????????????????????????????????????????????????????????
stroptokinase urokinase Alteplase Reteplase Tenecteplase
Plasma half-life (min) 18 15 4–8 11–14 20
?????? ?????????????????????????
A schematic model of fibrinolysis is demonstrated in Figure 8. Urokinase and tPA convert 
plasminogen into the active form – plasmin. Plasmin turns fibrin into degradation products 
that contain polypeptides and amino acids. Both tPA and urokinase could be inhibited 
by plasminogen activator inhibitor-1 and -2. On the other hand, alpha 2-antiplasmin and 
alpha 2-macroglobulin can inactivate plasmin. At the same time, thrombin-activatable 
fibrinolysis inhibitor may reduce the activity of plasmin.
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2.6.3 Contraindications for CDT
The potential candidates for CDT are evaluated for specific contraindications, which can 
be divided into absolute and relative. Although slight variations between the available 
protocols might occur, the general contraindications are presented in Table 5.
???????????????????????????????????????????????????????????????????????????? ?????????????????????????
J. (2010). 
Absolute contraindications Relative contraindications
Recent stroke or neurosurgery within 2 months Major surgery/trauma within 10 days
Major surgery within 2 weeks Hypertension >180 mmHg and diastolic >110 mmHg
Active bleeding disorder Cardiopulmonary resuscitation within 10 days
Gastrointestinal bleeding within 10 days Puncture of non-compressible vessel
Intracranial or spinal surgery within 3 months Intracranial tumour
Head injury within 3 months Pregnancy
Recent eye surgery
Diabetic haemorrhagic retinopathy
Hepatic failure
Bacterial endocarditis
?????? ????????????????????????????????????????
Thrombolytic treatment for ALLI is mostly administered intra-arterially. In a Cochrane 
review, Kessel and colleagues (Kessel et al. 2004) demonstrated that the intravenous 
administration of thrombolytics was less effective than intra-arterial delivery directly into 
the thrombus. In fact, the total dose of lytics in the case of intra-thrombotic administration 
was obviously lower but simultaneously offered higher local drug concentrations. 
Recently, new technical improvements in lytic therapy have been introduced. The data 
available on the results of such treatment are, however, limited. A Dutch randomized trial 
(Schrijver et al. 2015) compared CDT to ultrasound-accelerated thrombolysis. The rates 
Figure 8. A 
?? ?????????????????
??????????????????????
©Damir Vakhitov
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of technical success, severe adverse events and 30-day patency were comparable between 
the two methods. Ultrasound-accelerated thrombolysis, however, took significantly less 
time to achieve limb perfusion (Schrijver et al. 2015). High-dose thrombolysis has been 
suggested to offer significantly shorter treatment time without compromising the outcome 
in comparison to the standard-protocol CDT, as reported by Braithwaite and colleagues 
(1997). The more recent study by Plate and co-authors (Plate et al. 2006) prospectively 
evaluated high-dose pulse-spray with low-dose infusion alone and found no significant 
differences in regard to technical success and complications. The same authors found the 
re-interventions to be more frequent in patients treated with low-dose thrombolysis (Plate 
et al. 2006). 
The standard CDT is performed through a puncture in the contralateral groin (Figure 
9) or, occasionally, using an ipsilateral access. Local anaesthesia is used. The infusion of tPA 
is run through a multihole infusion catheter (e.g. a Cragg McNamara catheter [Medtronic, 
Minneapolis, Minn]) for a maximum of 48 hours. The current thrombolytic protocols 
are heterogenic in terms of the tPA dosage and treatment duration (Ebben et al. 2019). 
According to the same authors, lower doses of fibrinolytics lead to similar results at the cost 
of a longer treatment time but with a lower rate of bleeding complications. 
Heparin or low-molecular-weight heparins are administered alongside CDT to stop 
the propagation of thrombosis, to prevent new embolic events and to maintain collateral 
circulation, as described in the previous chapter. A Swedish study group suggested that 
similar revascularization rates could actually be achieved in patients receiving no heparin 
(Grip et al. 2014). In fact, the bleeding complication rates of those patients were comparable 
to the bleeding rates of the individuals treated with heparin infusions (Grip et al. 2014).  
???????????????????????????????????????????????
introduced “up and over” to the left side through the 
contralateral femoral artery. The insertion site in the 
groin is secured with a large adhesive bandage, which 
simultaneously compresses the puncture site and helps 
prevent “oozing bleeding”. ©Damir Vakhitov
33
2.6.5 Complications of thrombolysis
Haemorrhage, distal embolization and the development of compartment syndrome are the 
most common complications of CDT. In a review, which included five trials and 1,283 
patients (Berridge et al. 2013), the risk of bleeding was more likely in thrombolysis patients 
(8.8%) compared to surgery patients (3.3%). The trend was similar in regard to distal 
embolization (12.4% versus 0%, respectively) within the same 30-day period (Berridge et al. 
2013). It is of note that, in a recent Cochrane review, the evidence regarding an increased 
risk of major haemorrhage and distal embolization in thrombolysis patients was of low and 
very low quality, respectively (Darwood et al. 2018). The most dangerous haemorrhagic 
complication is, however, stroke, which occurs in approximately 1.3% of the patients 
(Berridge et al. 2013) and may lead to death. 
The information available in regard to compartment syndrome (CS) development during 
treatment with CDT is insufficient (Figure 10). Although sparsely reported (Freyer et al. 
2014), this serious complication usually occurs in up to 10% of the patients (Karnabatidis 
et al. 2011) and may lead to an increased risk of amputation and death (Eliason et al. 2003). 
The systemic consequences of CS are well recognized. Reperfusion oedema and excessive 
pressure inside the compartment may lead to tissue necrosis. The cell impairment results 
in the release of lactate dehydrogenase, intracellular potassium, creatine phosphokinase, 
phosphate, myoglobin and aldolase into the circulation (Petejova & Martinek 2014). 
The development of rhabdomyolysis may subsequently lead to renal failure. When CS 
is suspected, urgent actions must be taken. This includes four-compartment fasciotomy 
(Figure 11) either in a bilateral or a unilateral manner. Crystalloid fluids are administered to 
clear myoglobin, and forced diuresis is maintained. Placing the leg in an elevated position, as 
well as physiotherapy, rubber-band-assisted skin traction with a consequent wound closure 
(Figure 11) and negative-pressure wound treatment can reduce post-fasciotomy oedema. 
Nevertheless, free skin grafting may occasionally be required. 
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2.6.6 Prognosis
Most studies have focused on the short- or mid-term results of thrombolytic treatment. The 
available information on the long-term outcome is insufficient and difficult to compare due 
to heterogeneity. 
Despite the increasing use of newer mini-invasive endovascular techniques, the 
short-term amputation rates remain high and range from 10% to 30% (Byrne et al. 2014; 
Norgren et al. 2007). In a prospective population-based study from England that assessed 
Figure 11. Bilateral four-compartment fasciotomy. 
The fasciae are opened from the condyli level and 
continued subcutaneously down to the ankle. The 
wounds are left open and rubber bands attached to 
the skin edges for traction and subsequent wound 
closure with staples or sutures. ©Damir Vakhitov. 
(The patient has recovered and can walk.) 
Figure 10. Compartment syndrome. An oedemic 
muscle steps out of the lateral compartment after the 
fascia has been opened. ©Damir Vakhitov
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the outcome of all acute arterial peripheral events, over 70% of patients were either dead 
or dependent at the 6-month follow-up. The 5-year outcome was even more unfavourable, 
with almost 90% dead or dependent (Howard et al. 2015). In a large retrospective cohort 
study (Grip et al. 2017) that included 689 cases, the overall primary patency rate was 55.9% 
at 5 years, demonstrating superior results after embolic events (83.3%) over occluded stents/
grafts (43.3%). An overall amputation-free survival rate of 45.2% at 5 years was registered, 
being lowest (37.9%) with occluded stents/grafts (Grip et al. 2017). 
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3 Aims of the Study
1. To study whether signs of bacteria are present in the thrombi of patients with ALLI.
2. To study the reasons of early thrombolytic treatment failure.
3. To assess the long-term outcomes of patients with ALLI after the initial treatment
with CDT.
4. To assess the determinants of recurrent ALLI in patients initially treated with CDT.
4 Materials and Methods
4.1 Study population
This thesis is based on four original papers. Th ey co mprise on e pr ospective st udy, tw o 
observational retrospective single-centre studies and one observational retrospective two-
centre study (Table 6). The studies were p erformed at Tampere a nd Turku University 
Hospitals and Tampere University. The retrospective studies I, III and IV were based on 
prospective registries. Their data had been audited and additional information obtained 
from electronic case records and angiograms. The post-procedural angiograms in Study 
IV were evaluated to estimate the tibial runoff sufficiency by mea ns of the  cru ral index 
(Jalkanen et al. 2016; Wickström et al. 2017). Study II was based on prospectively 
collected information from patients with ALLI. Their thrombus aspirates were analysed 
in the laboratory of Tampere University by means of the quantitative polymerase chain 
reaction (qPCR). The results regarding the presence of bacterial DNA in the thrombi were 
confidentially transferred to the study group of vascular surgeons. The Ethics Committees 
of Tampere University Hospital and Turku University Hospital approved the 
studies. Informed consent was not required for Studies I, ?II and IV, while all patients 
gave their informed consent in Study II, in accordance with the study design and the 
instructions by the Ethics Committees. The dates and causes of death were obtained 
from electronic case records and from Statistics Finland.
37
38
Table 6. Summary of the numbers of studied patients and the main focus of each study
Study IV
Prognostic risk factors 
for the RALLI
Study I
Risk factors for the CDT 
failure
Study II
Evidence of the bacterial 
DNA presence in the 
thrombi
Study III
Long-term survival, 
patency and limb 
salvage
Study II
N=31
(Sept. 2014–Oct. 2016)
Study III
N=155
(Mar. 2003–Dec. 2014)
Study IV
N=303
(Mar. 2002–Dec. 2015)
Study I
?????
(Jan. 2002–Dec. 2011)
Studies I–IV
N=303 (Jan. 2002–Oct. 2016)
4.2 Methods
The study population comprises consecutive patients who were referred to Tampere and 
Turku University Hospitals. The studied patients presented with symptoms and signs of 
acute or acute-on-chronic lower limb ischaemia (Rutherford I–IIb). They were admitted 
to the hospital between March 2002 and December 2015. The patients were examined 
in the emergency room, with   laboratory tests and radiological (ultrasonography, CT 
or MRI) examinations performed as necessary. Patients with contraindications for 
thrombolysis or severe sensorimotor loss at presentation were managed with open vascular 
surgical procedures or, in some cases, amputation. These patients are not presented in the 
current work. Patients unfit for either of the invasive treatment modalities were treated 
conservatively and excluded from further analysis. 
4.2.1 Indications for treatment
The indications for treatment were the same in all the studies performed. They were based on 
the general symptoms that may be specific for ALLI. These often include acutely presented 
rest pain, claudication, cold sensation, discolouration, numbness and a motor deficit of the 
toes, foot or leg. If confirmed by the results of a clinical examination and, upon necessity, 
supported by radiological evidence, the indication for the treatment appeared clear.
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4.2.2 Thrombolytic procedure
Interventional radiologists performed the majority of the procedures. The technical aspects 
of the thrombolytic treatment were partially described in section 2.5.3. The procedures were 
carried out through the common femoral artery under local anaesthesia. A contralateral 
approach was preferred. The thrombus aspirates in Study II were obtained aseptically in 
the angiography laboratory before the initiation of thrombolysis. Otherwise, an infusion of 
tPA (Actilyse; Boehringer Ingelheim, Stockholm, Sweden) was instantly started once the 
Cragg-McNamara infusion catheter (Medtronic, Minneapolis, Minn.) was inserted inside 
the thrombotic mass. An initial bolus of 4 mg was given. The treatment continued with a 
0.5mg/h infusion for a maximum of two days, with the majority of control arteriographies 
performed every 24 hours. 
The end point of the CDT was complete flow restoration. The thrombolytic therapy 
continued in a 24-hour observation ward or an intensive care unit until the fibrinolysis 
was completed. Additional endovascular or open surgical modalities could be needed to 
achieve adequate distal perfusion.
4.2.3 Follow-up
The patients were followed-up for various periods of time. After discharge from the hospital, 
the first follow-up visit was routinely scheduled at one month post-procedurally. Further 
surveillance was arranged at different time points until the patient required no additional 
manipulations and was free of all signs and symptoms of critical limb ischaemia. The 
patients who were treated for proximal bypass graft or native arterial occlusions underwent 
further annual examinations at their community health centres. Symptomatic patients 
underwent additional examinations. The patients who underwent below-the-knee bypass 
surgery were followed up biannually at the hospital. Their toe pressure and ankle-brachial 
index were assessed at each visit, along with ultrasound examinations. Additional visits 
were arranged upon necessity. These were based on the clinical situation. 
4.2.4 Examination of thrombus aspirates for bacterial DNA presence
Study II evaluated the thrombi for bacterial DNA presence: any bacterial DNA and DNA 
of the S. mitis group. This group of bacteria comprises species most of which are from the 
oral cavity. These bacteria were found in thrombus aspirates of the coronaries and cerebral 
arterial wall samples in patients with acute coronary syndrome and cerebral aneurysms, 
respectively. The bacteria are known for their exceptional ability to bind platelets and 
to adhere to an endothelium, possibly suggesting its haematogenous means of spreading 
within the arterial flow.
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In brief, the presence of microbial DNA was discovered with qPCR. The patients’ own 
arterial blood served as a reference. The measurements were performed as duplicates or, in 
uncertain cases, as quadruples. The samples were marked bacterial-DNA-positive if there 
was an at least twofold difference in the relative amount of microbial DNA in comparison 
to the reference. 
4.2.5 Statistical analysis
IBM SPSS Statistics (IBM Corp. Armonk, NY) software was used to perform the 
statistical analyses. Fisher’s exact test and Chi-squared tests were used to compare 
categorical variables. The Mann-Whitney U test and the independent samples t-test were 
applied for continuous variables. In Study III, age was, for descriptive purposes, divided 
into age categories (≤64, 65–74, 75–82.5 and ≥83 years). Univariable analysis was carried 
out using a Cox proportional hazards model. The variables were tested for a proportional 
hazards assumption with a log-minus-log plot. In Study I, all parameters were tested in 
a backward stepwise binary logistic regression model. In Studies III and IV, only the 
significant parameters were tested in a multivariable Cox backward stepwise regression 
model. Kaplan-Meier analysis was used for the patency and survival analyses. A P-value 
<0.05 for Studies I, III and IV was considered significant. Due to the relatively small size of 
the cohort in Study II, the statistical significance level was set to ≤0.05 instead. 
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5 Results
5.1 Bacterial DNA presence in thrombus aspirates obtained 
before the initiation of thrombolysis (Study II)
A total of 31 arterial thrombus aspirates were obtained from patients with ALLI (Table 7), 
including thrombi from native arteries as well as bypass grafts (Table 8). Of all the positive 
arterial samples 18/20 (90%) contained DNA of the S. mitis group. The mean difference in 
the amount of any bacterial DNA (total bacterial DNA) in comparison with the reference 
was 12.1 (median 7.1). For the S. mitis group DNA, the mean difference was 29.1, while 
the median was 5.2-fold. The only factor that was associated with the presence of DNA of 
the S. mitis group in the thrombi was a history of previous arterial interventions, p=0.049.
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????????????????????????????????????????????????????????????????????????????????
Baseline demographics Study I
N=149
Study II
N=31
Study III
N=155
Study IV
N=303
Age, mean or median ?? ?? ?? ??
Sex, female N(%) ????????? ????????? ????????? ??????????
Diabetes, N (%) ????????? 10 (32.2) ????????? ?????????
Dyslipidaemia, N (%) ????????? ????????? ????????? 116 (38.3)
Arterial hypertension, N (%) 120 (80.5) 25 (80.6) ?????????? ??????????
Coronary heart disease, N (%) 66 (44.3) ???????? ????????? ??????????
Cerebrovascular disease, N (%) ????????? ??????? 21 (13.5) 43 (14.2)
??? ?????????????????????????? N/A ???????? 22 (14.2) 51 (16.8)
History of smoking within the last 5 years, N (%) ????????? 15 (48.4) 26 (16.8) 65 (21.5)
????????????????????????? ??????? 2 (6.5) ???????? ????????
????????????????????????? 60 (40.3) 10 (32.3) ????????? ??????????
Heart failure, N (%) 25 (16.8) ???????? ????????? 62 (20.5)
Duration of ischaemia, days, median 3 ? ??? 2
Ischaemia category, Rutherford, N (%)
Category I
Category IIa
Category IIb
?????????
50 (33.6)
????????
N/A
N/A
N/A
?????????
?????????
N/A
?????????
130 (43.0)
??????????
Proximal anatomic segment involved, N (%)
iliac
fem-pop
tibial
N/A
N/A
N/A
N/A
N/A
N/A
????????
????????
31 (20.0)
38 (12.5)
??????????
48 (15.8)
Table 8. The presence of bacterial DNA in native arterial and arterial bypass graft thrombi. 
Percentage presented within the subgroups of native arteries and conduits.
All patients
(N=31)
Positive total 
bacterial DNA
(N=20)
Positive for S. 
mitis group DNA
(N=18)
Type of thrombus aspirate, N (%):
Native artery
Bypass graft:
Autologous vein graft
Prosthetic conduit
?????????
???????
????????
?????????
????????
????????
10 (52.6)
????????
????????
5.2 Short-term outcomes (Studies I, II, III and IV).
Among the 303 ALLI cases (Table 7) managed with CDT, nearly 40% of the events in 
the native arteries were classified as embolism. Bypass graft occlusions were chiefly of 
thrombotic origin. The embolic events were associated with a history of atrial fibrillation. 
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Nearly a third of the cases were managed with thrombolysis as a monotherapy. The majority 
(>50%) required endovascular, open or hybrid procedures as an adjunct in order to achieve 
adequate distal perfusion. A total of 23% of the events were classified as a treatment failure 
(Table 9). Periprocedural complications are summarized in Table 10. 
The analysis of primary patency is presented in Figure 12. The post-procedural primary 
patency rates of native arteries were significantly better than those of bypass grafts.
????????????????????????????????????????????????????????????????????
Failure criteria Frequency, N (%)
Rapid progression of ischaemia requiring conversion to open surgery ???????
No lysis effect within two days of treatment ????????
Complete or partial lysis with inability to reopen run-off vessels ????????
Reocclusion within one month of thrombolysis 5 (3.4)
Major amputation above the ankle level due to ischaemia ????????
Termination of thrombolysis due to major bleeding 2 (1.3)
In-hospital death ???????
Table 10. Periprocedural complication rates
Complication types (%)
Major bleeding 6
Compartment syndrome 1.3
Intracranial bleeding and death ???
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Almost 9% (N=13/149) of the major amputations were performed within the first month 
after thrombolysis due to a failure to restore sufficient circulation in the limb (N=13/34 
[38%] within the failure group). Approximately 80% of the patients were alive at one year 
post-procedurally, with the amputation-free survival rate exceeding 60% (Figure 13).
Figure 12. Primary patency of native 
arteries and bypass grafts. Kaplan-
Meier survival analysis, p<0.001. 
Limbs at risk and percentage (in 
brackets) presented in the table.
Figure 13. Amputation-free 
survival after CDT for ALLI. 
Kaplan-Meier survival 
analysis. 
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5.2.1 Risk factors associated with treatment failure within a 30-day period 
Previous bypass grafting (odds ratio [OR] 0.18), dyslipidaemia (OR 0.16) and a delay in 
treatment initiation (OR 0.95 per day) negatively impacted on the success of thrombolysis 
in the binary logistic regression analysis. The trend was present throughout the post-
procedural follow-up when evaluated by Cox Regression analysis; see Figures 14–18.
Figure 14. Cumulative hazard of 
amputation or reocclusion in patients 
with native arterial and bypass graft 
events. Cox Regression analysis, 
p<0.001. Limbs at risk presented in 
the table.
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Figure 15. Cumulative hazard of 
amputation or reocclusion in patients 
with and without dyslipidaemia. Cox 
Regression analysis, p=0.031. Limbs 
at risk presented in the table.
Figure 16. Cumulative hazard of 
amputation or reocclusion in native 
arterial patients with and without 
dyslipidaemia. Cox Regression 
analysis, p>0.05. The vertical 
dashed line represents the level at 
which the standard error exceeds 
10%. Limbs at risk presented in 
the table.
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Figure 18. Cumulative hazard of 
amputation or reocclusion by the 
duration of ischaemia symptoms. 
Cox Regression analysis, 
p>0.05. The vertical dashed line 
represents the level at which the 
standard error exceeds 10%. 
Limbs at risk presented in the 
table.
?????????????????????????????
of amputation or reocclusion 
in bypass graft patients with 
and without dyslipidaemia. Cox 
Regression analysis, p>0.05. 
Limbs at risk presented in the 
table.
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5.3 Long-term outcomes (Studies III and IV)
Almost 80% of the patients underwent additional open, endovascular or hybrid procedures 
to preserve sufficient limb circulation. The long-term outcomes were significantly different 
between the patients with native artery and bypass graft occlusions. The primary patency 
rates after native-arterial events were significantly more favourable than the corresponding 
rates after bypass graft occlusions and, in particular, after autologous vein bypass graft 
thrombosis. The latter demonstrated the lowest primary patency rates at 9 years post-
procedurally (Figure 19). The long-term secondary patency rates showed an insignificant 
difference between native arteries and bypass grafts (Figure 20). 
????????????????????????? ?????????????
Kaplan-Meier survival analysis, p<0.001. 
Limbs at risk and percentage (in 
brackets) presented in the table.
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Predominantly bypass conduits were affected with the recurrent ischaemia, which, overall, 
occurred in over 40% of the cases within a median of 40 months.
Approximately 25% of the patients required major amputations during the follow-up. 
The amputation-free survival rate was 47% at 5 years and 24% at 10 years post-procedurally 
(Figure 13). The presence of rethrombosed prosthetic conduits was associated with superior 
limb salvage when compared to native arterial and vein graft thrombotic events, P=0.025. 
The most common cause of death was cardiovascular events (Figure 21). The cumulative 
survival of patients was 56% at 5 years and <30% at 10 years (Figure 22). 
Figure 20. Cumulative secondary 
patency. Kaplan-Meier survival 
analysis, p=0.88. Limbs at risk 
and percentage (in brackets) 
presented in the table.
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5.3.1 Independent risk factors negatively affecting long-term outcomes
Patency
Decreased primary patency rates were associated with the absence of antiplatelet and/or 
anticoagulant treatment after native arterial occlusions (hazard ratio [HR] 6.51), p<0.001. 
An increased risk of bypass graft rethrombosis was associated with diminished tibial runoff 
(HR 2.40), p<0.05. 
Figure 21. Distribution of 
causes of death in ALLI 
patients initially treated with 
CDT. Percentage provided. 
Figure 22. Cumulative 
survival of patients after 
treatment with CDT. 
Kaplan-Meier survival 
analysis.
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Major amputations
The occurrence of a bypass graft thrombosis (HR 14.77), p=0.01, was associated with an 
increased risk of major amputations.
Amputation-free survival
Age over 75 years was associated with diminished amputation-free survival rates (HR 2.01 
per age category), p=0.04.
Cumulative survival 
Age over 83 years (HR 5.23 per age category), p<0.001, and atrial fibrillation (HR 2.31), 
p=0.001, were associated with diminished cumulative survival rates. 
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6 Discussion
The current work focuses on the possible aetiological aspects of thrombosis and the long-
term outcome of thrombolytic treatment in patients with ALLI. Tampere and Turku 
University Hospitals serve as referral centres to a combined population of almost 2 million 
people; therefore, the data presented particularly in Study IV is among the largest available 
in the literature.
6.1 Evidence of bacterial DNA presence in thrombus 
aspirates of patients with ALLI
Our study revealed the presence of microbial DNA in the thrombus aspirates of patients 
with symptomatic arterial thrombosis of the lower extremities. DNA of the S. mitis group 
was predominantly presented in the thrombi. 
Previous studies (Pessi et al. 2013; Pyysalo et al. 2013, 2016) have found DNA of the 
S. mitis group to be the most common in thrombus aspirates from cerebral arterial wall 
samples and coronaries in patients with cerebral aneurysms and acute coronary events, 
respectively. Oral bacteria can access the arterial flow and reach the “destination site” via 
lesions in the oral cavity. Furthermore, micro-organisms can access atherosclerotic plaques 
from the vasa vasorum. These small vessels surround the arterial adventitia and provide 
nutrient supply. The bacteria of the S. mitis group have been shown to be able to bind 
thrombocytes (Bensing et al. 2001; Mitchell et al. 2007). The bacteria of this group can 
create thrombogenic and inflammatory biofilms after adhering to an endothelium. This 
allows other micro-organisms to attach as well (Kolenbrander et al. 2010). Bacteraemia 
may result in an accumulation of microbes in the plaque, which may lead to the subsequent 
development of a low-grade inflammation (Pessi et al. 2013). The rupture of a plaque 
inhabited by micro-organisms with a thrombocyte-binding potential may lead to the 
formation of a thrombus. This supports the potential role of such micro-organisms in 
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vascular thrombosis, which usually requires endothelial injury and the presence of platelets 
(Yeaman 2010). Bacteria of the oral cavity have been found in the endocardium, heart 
valves or atherosclerotic plaques (Kerrigan & Cox 2009). 
Although the results of our study are interesting, the information must be interpreted 
with caution. Currently, the role of bacteria in the setting of thrombosis is not understood 
completely, and there are some drawbacks in the study. The revealed “bacterial signature” 
in the thrombi of ALLI patients is, however, the first step towards understanding the 
mechanisms of possible bacterial involvement in the pathophysiology of thrombosis. 
6.2 Prognostic determinants of short-term outcome 
after treatment with thrombolysis 
A success rate of 77% was registered in Study I, and it is in accordance with the results 
of the available data from other centres (Kuoppala et al. 2008; Plate et al. 2009). Early 
failure was found to be associated with the presence of hypercholesterolaemia, prolonged 
ischaemia duration and previous bypass grafting. Attention must be paid to the first two 
determinants, as the last one will be discussed in the next section. 
The role of dyslipidaemia in the setting of ALLI has not been sufficiently studied. There 
is no strong data to support or reject the direct role of hypercholesterolaemia in lower-limb 
thrombotic or embolic events. There is, however, data to propose that dyslipidaemia may 
impair the endothelium-related relaxation and increase the vascular tone, in addition to 
decreasing the blood flow and increasing platelet aggregation (Komori et al. 1989). Such 
mechanisms may predispose patients to the occurrence of PAD, as reported by the same 
authors. Furthermore, this data can be supported by the fact that, in the Reduction of 
Atherothrombosis for Continued Health registry, statin therapy was associated with 
a 17% decrease in adverse cardiovascular event rates (Kumbhani et al. 2014). In our 
retrospective study, we could not demonstrate the prevalence of statin users and the lipid 
levels among the patients of the cohort. Nonetheless, based on the evolving data, we are 
prone to believe that statin treatment is important. In the recent European Society for 
Vascular and Endovascular Surgery guidelines released in March 2018, all patients with 
PAD are suggested to be prescribed statin therapy (Aboyans et al. 2018), thus supporting 
our findings. 
A delay in treatment initiation has been suggested to negatively impact on thrombolysis 
results (Working Party on Thrombolysis in the Management of Limb Ischemia 2003). The 
results of the STILE trial suggested that patients with acute symptoms lasting no longer 
than two weeks could be treated with thrombolysis (The Stile Investigators 1994). In 
our series, the difference between the success and failure groups in regard to the median 
duration of symptoms was insignificant (Study I). Nevertheless, in the logistic regression 
analysis, a prolonged duration of ischaemia was independently associated with an increased 
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risk of treatment failure by 5% per day. It is of note that the duration of symptoms is often 
difficult to evaluate exactly. This measure may be dependent on the individual differences 
in experiencing a sensory deficit and pain.  
6.3 Long-term outcomes of patients with ALLI 
after initial treatment with CDT
6.3.1 Patency
Despite the large number of additional procedures needed to preserve adequate distal 
perfusion, the results of our studies suggest that the long-term patency rates after the 
initial treatment with CDT are generally unfavourable. This is particularly true for bypass 
conduits, the primary patency rates of which drop to below 30% at 9 years post-procedurally. 
The primary patency rates after native arterial occlusions are higher, but they are dependent 
on the patients’ baseline characteristics and the presence of post-procedural medication. 
6.3.1.1 Native arteries
Our analysis has demonstrated that the absence of proper antiplatelet or anticoagulant 
therapy after native arterial occlusions is independently associated with recurrent ALLI 
(RALLI) events. While nearly 40% of native arterial occlusions were of embolic origin, 
they were significantly associated with the history of atrial fibrillation. Previous studies 
(Campbell & Ridler 2000; Forbes et al. 2002) suggested the importance of anticoagulation in 
the prevention of RALLI. This is particularly true for those in whom the condition develops 
due to cardiac reasons (Forbes et al. 2002). There is, however, insufficient data available 
to reject or support the long-term use of anticoagulants in patients with no intracardiac 
thrombus or atrial fibrillation (Forbes et al. 2002). The efficacy of acetylsalicylic acid (ASA) 
has been documented in a large number of studies (Eikelboom et al. 2012). The use of dual 
antiplatelet therapy appears to be promising in reducing post-procedural complications in 
patients with PAD (Beiswenger et al. 1922; Katsanos et al. 2015). Additionally, the data 
from a recent trial proposed that a combination of aspirin with rivaroxaban for secondary 
cardiovascular prevention was superior to ASA alone or rivaroxaban alone (Eikelboom et 
al. 2017). Although we could not draw final conclusions on the regime for post-procedural 
medication in the current study, it is clear that the absence of such treatment could be 
decisive. 
6.3.1.2 Bypass grafts
More advanced stages of PAD are frequent among the cases of bypass graft occlusions. 
The progressing PAD may predispose these patients to poorer results in comparison to 
patients with native arterial events. Vein conduits are usually used to correct more distal 
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(below-knee), extensive lesions, whereas synthetic grafts are often used above the knee. 
Therefore, the latter group of patients is usually characterized with less-severe underlying 
PAD. Although CDT is generally an effective remedy in conduit recovery, the patency of 
such grafts is, nevertheless, poor (Chalmers et al. 1995). This phenomenon may be partially 
explained by the progression of atherosclerosis and a worsened outflow as a result. In our 
series, an impaired tibial outflow was an independent predictor of bypass graft reocclusions. 
Furthermore, the development of a prothrombotic layer in the prosthetic conduits and 
vein graft endothelial alterations could also lead to an unfavourable outcome (Conrad et al. 
2003). According to another study, occluded vein grafts are unlikely to yield durable post-
thrombolytic patency (Nackman et al. 1997). Although our results generally confirm the 
existing data (Grip et al. 2017; Kuoppala et al. 2008), a more precise comparison is difficult 
to achieve owing to the diverse selection of end points, study structures and methods used. 
6.3.2 Major amputations and amputation-free survival
In our series, over a quarter of the ALLI patients underwent major amputations. The main 
reasons were RALLI and an inability to obtain sufficient distal perfusion. The increased 
risk of amputation was associated with the occurrence of graft thrombosis. The majority of 
amputations were performed within thirty days from the RALLI. The only independent 
parameter to be associated with unfavourable amputation-free survival was an age of over 
75 years (Study III).
The amputation-free survival rates of patients with synthetic conduits were superior 
to the rates of those who had suffered native arterial events and autologous vein graft 
thrombosis events (Study III). This trend was also similar after RALLI (Study IV). The 
data available to address this issue is inadequate (Byrne et al. 2014; Grip et al. 2017; 
Genovese et al. 2016; Taha et al. 2015; Nackman et al. 1997) and difficult to compare to 
our results due to the heterogeneity of the works. According to our series, almost all of the 
patients with recurrent events in native arteries presented with considerably diminished 
outflow. The inability to re-obtain adequate circulation led to major amputations. Vein 
bypass grafts could be exposed to irreversible ischaemic changes in the endothelium, which 
resulted in poor patency rates. As described earlier, vein conduits are generally used in 
distal, below-the-knee bypass surgery. The inability to restore circulation in the limb, along 
with advancing distal atherosclerotic changes, would apparently predispose many of these 
patients to major amputations. Conversely, prosthetic grafts are frequently used in more 
proximal segments. Even though the patency of recovered conduits is generally poor, the 
extremity can be saved by means of additional surgical operations.
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6.3.3 Cumulative survival
Poor short-, medium-, and long-term survival of elderly patients after acute ischaemic events 
of the lower extremities has been acknowledged lately (Grip et al. 2017; Koraen et al. 2011; 
Kuoppala et al. 2008; Schrijver et al. 2016; Taha et al. 2015). Increasing age has been shown 
to be significantly associated with higher mortality rates within five years from CDT (OR 
1.07/year) (Grip et al. 2017). In our study, we confirmed these findings, identifying poor 
mid- and long-term post-lytic survival rates (HR 5.23/per age category). The majority of 
deaths resulted from cardiovascular causes, especially in octo- and nonagenarians. Age is, 
nevertheless, a non-modifiable, natural determinant. The association of advanced age with 
mortality is, therefore, understandable.
The influence of atrial fibrillation (AF) on the mortality of ALLI patients managed with 
thrombolysis is uncertain. Moreover, the existing data are conflicting. Nonetheless, the 
accumulating evidence supporting the role of AF in the increased mortality (Andersson et 
al. 2013) and the correlation with cardiovascular diseases (Odutayo et al. 2016) supports our 
findings. In the cohorts studied, the patients with atrial fibrillation were mainly prescribed 
warfarin. It should be emphasized that, due to the changing international normalized ratio 
and difficulties in its maintenance within a certain range, the efficacy of warfarin may be 
insufficient in some patients (Birman-Deych et al. 2006). It remains debatable whether 
newer anticoagulation alternatives could offer better protection and increase the survival 
rates of ALLI patients.
6.4 Limitations of the study
In our series, both prospective and retrospective cohorts were analysed. Study II is a 
prospective work, and it may be criticized for its relatively small number of samples. It was a 
“pioneer” study, in which it took our team some time to recruit the patients and process the 
samples. Nonetheless, the results are clear and the work opens good perspectives for future 
projects. We reported the presence of bacterial DNA. The study, however, did not reveal 
the presence of living micro-organisms or their influence on thrombosis. The problem 
was difficult to overcome because staining and culturing in our study would have had a 
rather limited potential. In contrast, the use of qPCR was accurate. We admit that the 
presence of microbial DNA in thrombi can also take place if the binding of bacteria with 
platelets occurs elsewhere in the circulatory system. Furthermore, inflammatory cells with 
eliminated microbial DNA fragments could also be attracted to the platelet aggregation 
site. However, the multi-fold differences in the volumes of DNA discovered in the thrombi 
suggest their possible role in the course of the thrombotic process. The function that 
bacteria serve and whether the function is important remain to be studied further. 
Although based on a prospectively maintained registry, Studies I, III and IV are 
retrospective, which is a limitation. Nonetheless, they include relatively large numbers of 
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patients. Furthermore, the same investigators processed the data, which we hope could 
reduce the risk for errors. One final issue is the selection bias. The patients were selected and 
underwent thrombolytic treatment based on the clinical assessment of a vascular specialist. 
6.5 Future perspectives
The aetiology and pathogenesis of ALLI has been gradually changing. The patients 
increasingly present with atherosclerosis-associated thrombosis rather than embolism. 
Currently, vascular surgeons deal with elderly patients who have multiple cardiovascular 
comorbidities. This often requires decision-making in a multidisciplinary group of 
specialists. Increasing obesity has also become an obstacle. According to the World Health 
Organization (2018), excess weight and obesity are now dramatically on the rise even in low- 
and middle-income countries and have become major risk factors for cancer, cardiovascular 
diseases and diabetes. In this setting, the role of open surgery as an initial treatment 
modality may face further recession, whereas minimally invasive, endovascular procedures 
will appear more appropriate particularly for the treatment of ALLI. The recent results of 
the Compass trial (Eikelboom et al. 2017) that suggest the use of rivaroxaban and aspirin 
as well as the increasing use of statins in PAD patients (Kumbhani et al. 2014) may have 
a positive impact on the outcome. Further competition between medical companies will 
probably reduce the costs of pharmacomechanical thrombolysis. The use of this method will 
permit reduced treatment times and decreases in overall expenses. It is, however, unlikely 
that the existing form of pharmacomechanical thrombolysis will completely replace CDT. 
The role of aspiration thrombectomy in ALLI treatment is possibly underestimated in 
some vascular centres and, in fact, remains unjustified. Furthermore, the research on the 
role of bacterial inflammation in the pathogenesis of thrombosis could possibly bring new 
therapeutic options in the long term. 
The aforementioned aspects raise new questions that we have currently no answers to. 
Further investigations are needed not only from the clinical viewpoint but also from the 
economic stand. This will benefit patients, health care practitioners and society as a whole. 
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?? ???????????
1. Bacterial DNA, particularly of the S. mitis group, is present in the thrombi of 
patients with ALLI. The presence of bacterial signs is significantly associated with a 
history of previous arterial interventions.
2. The majority of ALLI cases can be successfully managed with CDT. Patients 
presenting with hypercholesterolaemia, a prolonged duration of ischaemia and 
previous bypass grafting are at a higher risk of CDT failure in the short term. 
3. Although multiple additional procedures are needed to preserve adequate distal 
perfusion after treatment with CDT, the long-term amputation-free survival rates 
are unfavourable. 
4. Recurrent acute lower limb ischaemia occurs frequently, as over 40% of patients 
are exposed to this condition. Bypass grafts are at a higher risk of reocclusions. The 
absence of appropriate post-thrombolytic anticoagulant or antiplatelet treatment 
after native arterial events is independently associated with the occurrence of 
RALLI. A diminished outflow is independently associated with rethrombosis in 
bypass grafts. 
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Independent Factors Predicting Early Lower
Limb Intra-arterial Thrombolysis Failure
Damir Vakhitov,1,2 Velipekka Suominen,1,2 Janne Korhonen,2,3 Niku Oksala,1,2
and Juha-Pekka Salenius,1,2 Tampere, Finland
Background: Risk factors for early catheter-directed intra-arterial thrombolysis failure in acute
lower limb ischemia remain unclear.
Methods: One hundred forty-nine limbs with acute artery or bypass graft thrombosis underwent
catheter-directed thrombolysis (maximum of 48 hours). A retrospective data analysis was
carried out to assess possible risk factors for early, 30-day treatment failure.
Results: Seventy-nine men (53%) and 70 women (47%) with a median age of 70 (range
32e93) years were treated. Treatment outcomes were determined as success (N ¼ 115,
77%) or failure (N ¼ 34, 23%). The failure criteria comprised rapid progression of ischemia
(N ¼ 4, 2.7%) and major bleeding complications (N ¼ 2, 1.3%), both requiring thrombolysis
termination and surgery. Inability to reopen native arteries/grafts (N ¼ 10, 6.7%), run-off vessels
(N ¼ 10, 6.7%), in-hospital death (N ¼ 4, 2.7%), the need for major amputation (N ¼ 13, 8.7%),
and reocclusions (N ¼ 5, 3.4%) within the 30-day follow-up period were also considered as fail-
ures. Multivariate analysis of the risk factors’ impact on the success of thrombolysis revealed
such independent parameters as hypercholesterolemia (OR 0.16, 95% CI 0.06e0.42, P <
0.0001), previous bypass grafting of the ipsilateral limb (OR 0.18, 95% CI 0.06e0.53,
P ¼ 0.002), and duration of ischemia prior to the initiation of thrombolysis (OR 0.95, 95% CI
0.91e0.99, P ¼ 0.009, per day).
Conclusion: According to our results, factors independently predicting early failure include
hypercholesterolemia, previous bypass grafting, and a delay in treatment initiation. Moreover,
catheter-directed intra-arterial thrombolysis can be considered safe and effective in the treat-
ment of acute lower limb ischemia.
INTRODUCTION
For more than 20 years, intra-arterial catheter-
directed thrombolysis has been used widely for the
treatment of lower limb acute ischemia. Previous
results1e3 suggest that the method itself is safe and
effective, with a success rate of approximately
70e80%. Good run-off vessels and intrathrombotic
infusion have been shown to bemajor determinants
of a successful immediate outcome of thrombolytic
therapy.4e6 Severe stages of ischemia before throm-
bolysis initiation, on the other hand, are associated
with an increased amputation rate.2,7,8
To date, a number of studies have analyzed the
possible role of comorbid conditions in early and
long-term outcome of lower limb intra-arterial
thrombolysis.1,2,4,7e10 According to the available
literature, diabetes mellitus (DM) and coronary
heart disease (CHD) are associated with poor post-
procedural outcome.2,4,7,8 Furthermore, some
studies have demonstrated a distinct relationship
between thrombolysis-related mortality and factors
such as cerebrovascular disease, chronic renal insuf-
ﬁciency, female gender, and increasing age.2,7 These
results are not, however, consistent, as other inves-
tigators have suggested quite the contrary.1,11
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Patients with acute ischemia often have multiple
comorbid conditions that may affect their long-term
prognosis despite successful thrombolysis.2 More-
over, the progression of underlying peripheral arte-
rial disease over time can worsen the clinical
picture. Consequently, in this retrospective,
vascular registry‒based study, we decided to focus
particularly on the early outcome of thrombolytic
therapy. Apart from the aforementioned studies,
most of which concentrated on factors associated
with major amputation and mortality after throm-
bolysis, we decided to look at the problem from
another point of view, by trying to deﬁne the factors
associated with the failure of thrombolysis itself. We
hypothesized that certain cardiovascular risk factors
and conditions have a direct impact on the early
outcome.
METHODS
Patients
This study was a retrospective analysis of consecu-
tive patients (N ¼ 327) referred to Tampere Univer-
sity Hospital (TAUH), Finland, for acute ischemia
between January 2002 and December 2011. TAUH
serves as a tertiary vascular surgical referral center
for approximately 1.2 million people. Patients with
symptoms or signs of category IeIIb acute limb
ischemia12 presenting with angiographic evidence
of native artery or bypass graft thrombosis were
included in the study on an intention-to-treat basis
(N ¼ 144). During the study, 5 patients were
referred twice. All these patients were treated with
thrombolysis, and the actual study group thus
comprised 149 limbs. Patients with progressive
sensorimotor changes, clinically or radiologically
identiﬁed embolic events, or contraindications for
thrombolysis (N ¼ 182), as well as those in whom
guide-wire or catheter introduction was, for any
reason, unsuccessful (N¼ 1), were treated surgically
and excluded from further analysis.
Thrombolysis Protocol and Follow-up
All procedures were performed under local anes-
thesia by an interventional radiologist. Percuta-
neous mechanical thrombectomy was not used in
the cohort observed. The catheter was placed in the
thrombotic mass and the recombinant tissue plas-
minogen activator alteplase (Actilyse; Boehringer
Ingelheim, Stockholm, Sweden) was administered
as an initial 4-mg bolus, followed by a continuous
0.5-mg/hr infusion lasting for a maximum of 48 hr.
At the same time, the patients were administered
low-molecular-weight heparins (LMWHs) enoxa-
parin sodium (Klexane; Sanoﬁ-Aventis, Maisons-
Alfort, France) 40 mg twice per day subcutaneously
or dalteparin sodium (Fragmin; Pﬁzer, Puurs,
Belgium) 5000 IU twice per day subcutaneously.
The patients then remained in 24-hr observation
with blood tests (full blood count, potassium,
sodium, creatinine, creatine kinase, myoglobin)
controlled at least twice daily. Angiography controls
were performed every 24 hr. Necessary surgical or
endovascular procedures (percutaneous angioplasty
[PTA], or stenting) were performed upon comple-
tion of thrombolysis. In cases of successful mono-
therapy‒thrombolysis, when blood clotting reason
remained unclear, the patients underwent addi-
tional examinations (hematologic, cardiologic,
internal medicine). Warfarin and/or combinations
of other drugs were administered for various periods
in these cases (data not shown). During the 30-day
follow-up visit, clinical status was assessed using
the ankleebrachial index, toe-pressure assessment,
and an ultrasound examination if needed (data not
shown).
Comorbid Conditions
Data from patient ﬁles and the vascular registry
were collected systematically by 1 examiner
(D.V.). The following risk factors from case records
were included in the analysis: age; gender; diabetes
mellitus; hyperlipidemia; hypertension; heart
failure; smoking within 5 years; cardiovascular
diseases (peripheral artery disease [PAD], coronary
heart disease [CHD], cerebrovascular disease);
chronic renal failure; and severity of ischemia. The
diagnosis for each disease was considered positive
if it had been previously established at the hospital
or mentioned in the referral, or if the patient was
on appropriate medication. The diagnosis of PAD
was based on vascular changes in a digital subtrac-
tion angiogram (DSA) and deﬁned as a narrowing
of the arterial lumen of >50% in any arterial
segment of the lower limbs. In addition, information
on the duration of acute symptoms, previous
vascular interventions, and aneurysmal disease
were searched for and included in the analysis.
Outcome Measures
The treatment was considered successful (success
group) if the native vessels or bypass grafts treated
with thrombolytic therapy were patent upon the
completion of thrombolysis and if acute symptoms
had resolved and the achieved clinical status
remained stable for 1 month. The need for addi-
tional minor surgical (endarterectomy, patch plasty,
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short segment jump graft bypass) and/or endovas-
cular manipulations (PTA, stenting) after effective
thrombolysis was not considered as failure.
The failure criteria (failure group) comprised
rapid progression of ischemia and major bleeding
complications, both requiring thrombolysis termi-
nation and surgery. Inability to reopen native
arteries/grafts, run-off vessels, in-hospital death,
need for major amputation, and reocclusions within
the 30-day follow-up period were also considered as
failure. The incidence of major bleeding (intracere-
bral hemorrhage, intestinal bleeding, or puncture-
site bleeding requiring surgical intervention) was
assessed to evaluate the safety of thrombolysis.
Data Analysis
Statistical analyses were carried out using the
SPSS statistical software (SPSS, Inc., Chicago, IL,
USA). Dichotomous variables were analyzed
with the chi-squared test. Due to the skewed
distribution of data, continuous variables were
analyzed using the ManneWhitney U-test, and
thus the data are presented as median and range.
To assess the association of various risk factors
with thrombolysis outcome, both univariate and
backward stepwise logistic regression analyses
were used. The latter was performed to evaluate
the independent role of various factors in throm-
bolysis outcome. For stepwise criteria, a P value
of 0.05 was speciﬁed for entry and 0.10 for
removal. P < 0.05 was considered statistically
signiﬁcant. P < 0.06 was considered nearly statis-
tically signiﬁcant.
RESULTS
Of the 149 patients who underwent thrombolysis
during the study period, there were 79 men (53%)
and 70 women (47%), with a median age of 70
(range 32e93) years. Table I shows the distribution
of comorbidities and other variables between the
groups. Hypercholesterolemia, previous bypass
grafting, and peripheral arterial disease were signif-
icantly more frequent among those with thrombol-
ysis failure.
Thrombolysis was successful in 115 (77%) of 149
cases. Thrombolytic therapy was sufﬁcient as
a monotherapy in 36 cases (24% of 149 cases), but
in 60 cases (40%) an additional endovascular proce-
dure was required to achieve adequate distal perfu-
sion. Additional minor surgical operations after
effective thrombolysis were done in 16 cases
Table I. Patients’ characteristics (data shown as per limb treated)
Variables Total (n ¼ 149) Success (n ¼ 115) Failure (n ¼ 34) P-value
Median agea [n (%)] 70 (32e93) 71 (32e93) 68 (50e93) 0.342
Gender, femaleb [n (%)] 70 (47%) 50 (43.5%) 20 (58.8%) 0.115
Arterial hypertensionb [n (%)] 120 (80.5%) 91 (79.1%) 29 (85.3%) 0.425
Atrial ﬁbrillationb [n (%)] 60 (40.3%) 44 (38.3%) 16 (47.1%) 0.358
Heart failureb [n (%)] 25 (16.8%) 20 (17.4%) 5 (14.7%) 0.713
Hypercholesterolemiab [n (%)] 70 (47%) 43 (37.4%) 27 (79.4%) <0.0001*
Diabetesb [n (%)] 26 (17.4%) 18 (15.7%) 8 (23.5%) 0.288
Smokingb [n (%)] 41 (27.7%) 28 (24.3%) 13 (39.4%) 0.089
Previous bypass graftingb [n (%)] 76 (51%) 51 (44.3%) 25 (73.5%) 0.003*
Aneurysm proximallyb [n (%)] 7 (4.7%) 6 (5.2%) 1 (2.9%) 0.582
Previous vascular intervention
within 1 monthb [n (%)]
13 (8.7%) 9 (7.8%) 4 (11.8%) 0.475
Duration of symptomsa [median
number of days (range)]
3 (1e60) 3 (1e30) 2 (1e60) 0.962
Coronary diseaseb 66 (44.3) 47 (40.9%) 19 (55.9%) 0.122
Cerebrovascular diseaseb 19 (12.8%) 15 (13%) 4 (11.8%) 0.844
Peripheral arterial diseaseb 116 (77.9%) 85 (73.9%) 31 (91.2%) 0.033*
Renal insufﬁciencyb 7 (4.7%) 7 (6.1%) 0 (0%) 0.141
Severity of ischemia
Rutherford I 85 (57.0%) 64 (55.7%) 21 (61.8%)
Rutherford IIa 50 (33.6%) 40 (34.8%) 10 (29.4%) 0.814
Rutherford IIb 14 (9.4%) 11 (9.6%) 3 (8.8%)
aIndependent-samples ManneWhitney U-test.
bPearson’s chi-squared test for dichotomous variables.
*P < 0.05 (statistically signiﬁcant).
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(10.7%) and a combination of thrombolysis, endo-
vascular, and open minor surgery in 3 cases (2%).
The minor amputation rate after successful throm-
bolysis was 0.7% (N ¼ 1).
The reasons for thrombolysis failure are summa-
rized in Table II. In the failure group (N ¼ 34, 23%)
major reconstructive surgery was required in half of
the group’s cases (N ¼ 17, 11.4%). All the amputa-
tions in the failure group were major (N ¼ 13),
demonstrating an 8.7% rate within the whole
patient group treated with thrombolysis. Four in-
hospital deaths occurred in the course of treatment
with alteplase (2.7% of 149 cases). Two patients
died from septicemia, 1 from acute myocardial
infarction and 1 from complications after massive
thromboembolism. There were 2 major bleeding
complications (puncture site), both managed surgi-
cally (1.3% of 149 cases).
In the univariate analysis, hypercholesterol-
emia, previous bypass grafting, and peripheral arte-
rial disease were found to be signiﬁcant predictors
of thrombolysis failure. Prolonged duration of
symptoms showed a nearly signiﬁcant association
(Table IIIa). In the backward stepwise logistic
regression analysis including all the factors (Table
IIIb), the parameters that independently impacted
the success of thrombolysis leading to failure
were hypercholesterolemia (odds ratio [OR] 0.16,
95% conﬁdence interval [CI] 0.06e0.42, P <
0.0001), previous bypass grafting (OR 0.18, 95%
CI 0.06e0.53, P ¼ 0.002), and prolonged duration
of symptoms (OR 0.95, 95% CI 0.91e0.99, P ¼
0.009, per day).
DISCUSSION
In this study we found thrombolysis to be an effec-
tive treatment modality for patients with category
IeIIb acute limb ischemia. The achieved success
rate of 77% is an improvement compared with our
institution’s previously reported data (59.2%),13
and is in accordance with results from other investi-
gators.1e3,7 Our study has also demonstrated that
hypercholesterolemia, previous bypass grafting,
and prolonged duration of symptoms can predict
lower limb intra-arterial thrombolysis failure.
Furthermore, our thrombolysis protocol seems to
be safe as the major bleeding complications rate
was only 1.3%.
The role of hypercholesterolemia in the outcome
of thrombolytic therapy for acute lower limb
ischemia has not been thoroughly studied. To our
knowledge, only 3 research groups have assessed
this subject previously, and they came to the conclu-
sion that hypercholesterolemia plays no signiﬁcant
role in the sequelae of intra-arterial thrombolysis,
thus contradicting our results.1,3,11 It must be
emphasized, however, that the aforementioned
studies differ in regard to study end points, cohort
size, patients’ demographic data, and statistical anal-
ysis used, which makes it difﬁcult to compare them
with our study. Furthermore, as information con-
cerning the presence of hypercholesterolemia was
not available for all participants in the study by Plate
and colleagues, any deﬁnitive conclusions on its role
would be unjustiﬁed.1 Nevertheless, the current
data on vascular pathophysiology support the idea
of hypercholesterolemia’s impact on throm-
bosis,14,15 thus making the results of our study
explainable.
Another major factor determining thrombolysis
success is previous bypass grafting of the ipsilateral
limb. Although occluded bypass grafts can often be
successfully reopened with thrombolysis, reocclu-
sion and long-term patency rates are poor.1,9,16,17
Our ﬁndings support these earlier results. Worsened
outﬂow as a result of PAD progression may partly
explain this phenomenon. It has also been proposed
that endothelium alterations in the bypass veins
and the development of a thin prothrombotic layer
in synthetic grafts could result in thrombolysis
failure.18
A delay in treatment initiation is also thought to
have a negative impact on the results of thrombo-
lytic therapy.8,19,20 The results of the STILE trial
suggest that thrombolytic therapy may be offered
to patients with acute symptoms lasting for no
longer than 2 weeks. In our cohort there was no
signiﬁcant difference in the median duration of
Table II. Reasons for failure
Reasons
Frequency
[N (%)]
Rapid progression of ischemic
changes during the thrombolytic
therapy requiring conversion to
open surgery
4 (2.7%)
No lysis effect within 2 days
of treatment
10 (6.7%)
Complete or partial lysis with
inability to reopen run-off vessels
10 (6.7%)
Reocclusion within 1 month
of thrombolysis
5 (3.4%)
Major amputation (above the
metatarsal level) within 1 month
of thrombolysis as a result of
inability to obtain adequate
distal perfusion
13 (8.7%)
Termination of thrombolysis due
to major bleeding
2 (1.3%)
In-hospital death 4 (2.7%)
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symptoms between the success and the failure
groups (Table I). The backward stepwise regression
analysis, however, showed that the duration of
symptoms is an independent risk factor for throm-
bolysis failure and that the risk of failure increases
by 5% per day. This ﬁnding may be weakened by
the fact that symptom duration is a subjective
measure as patients experience pain and sensory
loss quite differently. This applies particularly to
those with a development of sensory changes due
to diabetic neuropathy.
There are several limitations to our study; the
main drawback is its retrospective design, involving
possible data issues associated with the use of
hospital discharge histories and patient case records.
Consequently, miscoding and a lack of clinical infor-
mation may cause uncertainty in the results.
However, the multiple admissions of the subjects
to our hospital due to comorbidities prior to the initi-
ation of the current study made data collection
easier and, we believe, more accurate. Furthermore,
possible data errors and miscoding would have been
similar for all patients enrolled. Another potential
issue is the selection bias, as patients were selected
for thrombolysis according to the surgeon’s clinical
assessment with no strict inclusion or exclusion
criteria. The selection of treatment options also
depended on the availability of the interventional
radiologic service, which is not provided on
a 24-hr basis at our hospital.
In conclusion, catheter-directed intra-arterial
thrombolysis seems to be safe and effective in
acute or subacute lower limb ischemia. Non-
hypercholesterolemic patients with a short duration
of ischemic symptoms presenting with thrombotic
events of native arteries can beneﬁt the most from
thrombolytic treatment. However, when thrombol-
ysis fails, the prognosis is poor as almost 40%
(within the failure group) of patients treated require
major amputations within 1 month. Our study has
produced novel information about the possible
role of hypercholesterolemia in the process of
thrombolysis failure. This ﬁnding, however,
requiresmore research before deﬁnitive conclusions
can be drawn.
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Bacterial signatures in thrombus aspirates of patients
with lower limb arterial and venous thrombosis
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ABSTRACT
Objective: Increasing data supports the role of bacterial inﬂammation in adverse events of cardiovascular and cere-
brovascular diseases. In our previous research, DNA of bacterial species found in coronary artery thrombus aspirates and
ruptured cerebral aneurysms were mostly of endodontic and periodontal origin, where Streptococcus mitis group DNA
was the most common. We hypothesized that the genomes of S mitis group could be identiﬁed in thrombus aspirates of
patients with lower limb arterial and deep venous thrombosis.
Methods: Thrombus aspirates and control blood samples taken from 42 patients with acute or acute-on-chronic lower
limb ischemia (Rutherford I-IIb) owing to arterial or graft thrombosis (n ¼ 31) or lower limb deep venous thrombosis
(n ¼ 11) were examined using a quantitative real-time polymerase chain reaction to detect all possible bacterial DNA and
DNA of S mitis group in particular. The samples were considered positive, if the amount of bacterial DNA in the thrombus
aspirates was 2-fold or greater in comparison with control blood samples.
Results: In the positive samples the mean difference for the total bacterial DNA was 12.1-fold (median, 7.1), whereas the
differences for S mitis group DNA were a mean of 29.1 and a median of 5.2-fold. Of the arterial thrombus aspirates, 57.9%
were positive for bacterial DNA, whereas bacterial genomes were found in 75% of bypass graft thrombosis with 77.8% of
the prosthetic grafts being positive. Of the deep vein thrombus aspirates, 45.5% contained bacterial genomes. Most (80%)
of bacterial DNA-positive cases contained DNA from the S mitis group. Previous arterial interventions were signiﬁcantly
associated with the occurrence of S mitis group DNA (P ¼ .049, Fisher’s exact test).
Conclusions: This is the ﬁrst study to report the presence of bacterial DNA, predominantly of S mitis group origin, in
the thrombus aspirates of surgical patients with lower limb arterial and deep venous thrombosis, suggesting their
possible role in the pathogenesis of thrombotic events. Additional studies will, however, be needed to reach a ﬁnal
conclusion. (J Vasc Surg 2018;67:1902-7.)
Clinical Relevance: This is the ﬁrst study to report the presence of bacterial DNA, predominantly of Streptococcus mitis
group origin, in the thrombus aspirates of patients with lower limb arterial and deep venous thrombosis. Interestingly, the
occurrence of S mitis group DNA seems to be signiﬁcantly associated with previous vascular manipulations. It remains to
be established whether these ﬁndings play a role in the actual thrombosis.
Bacterial inﬂammation has long been suggested to
contribute to inﬂammation of atherosclerotic plaques,
either directly or by indirect mechanisms, where inﬂam-
mation at nonvascular sites can contribute to the
progression of the lesions. Proposed bacteria include
respiratory pathogens and periodontal bacteria as well
as bacteria from the gastrointestinal tract.1 One group
of common oral bacterial species, namely, Streptococcus
mitis group, has been shown to have an exceptional
ability to adhere to an endothelial surface and bind
platelets as well.2,3 Previous studies4-6 showed that S
mitis group DNA was predominant in thrombus
aspirates from coronary arteries and cerebral arterial
wall samples in patients with acute coronary events
and cerebral aneurysms respectively. The S mitis group
comprises 13 species.7 Most of these bacteria can be
found in the oral cavity of healthy individuals.
Based on these previous studies, it is likely that oral
pathogens may play a certain role in the pathogenesis
of cardiovascular diseases.4-6 To the best of our
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knowledge, there are no studies depicting the role of
dental or periodontal bacteria in the thromboembolic
events of lower limbs and whether they are present in
venous thrombosis. Thus, the target bacteria for our
study were S mitis group because their DNA could be
found in almost 80%4 of the thrombus aspirates and in
the majority of the arterial wall samples5,6 of the patients
with cardiovascular and cerebrovascular diseases,
respectively. We hypothesize that the signs of these oral
pathogens can equally be found in the thrombus aspi-
rates of peripheral vessels of the lower limbs.
METHODS
Patients
This prospective study analyzed data from consecutive
patients (N ¼ 62) referred to Tampere University Hospital,
Tampere, Finland, for acute or acute-on-chronic lower
limb arterial, arterial bypass graft, or deep venous throm-
bosis from September 2014 to October 2016.
Inclusion criteria. Patients with symptoms or signs of
acute or acute-on-chronic lower limb ischemia (Ruth-
erford class I-IIb)8 presenting with angiographic evidence
of native artery or bypass graft thrombosis (n ¼ 31) and
patients presenting with deep venous thrombosis of the
iliofemoral segment with symptoms’ duration no longer
than 2 weeks (n ¼ 11).
Exclusion criteria. Patients with progressive sensori-
motor changes or contraindications for thrombolysis
(n ¼ 20). Those patients were treated surgically and
excluded from further analysis. Based on our previous
experience, thrombus aspirates from those patients
were not obtained owing to increased sample
contamination risk.9,10 The patients included in the
study were treated with thrombolysis, and the
actual study group thus comprised 42 cases (Table).
The study was approved by the ethics committee of
the hospital, and all the patients included gave
informed consent.
Specimen processing
Aspiration of thrombus samples was performed asepti-
cally in an angiography laboratory by an interventional
radiologist. The antiseptic routinely used for skin disin-
fection was a denatured ethanol solution (A12T Dilutus
80%; Berner, Helsinki, Finland) being effective against
both aerobic and anaerobic pathogens.11 Patients
received no antibiotic therapy at admission to the hospi-
tal or later during the procedure. The procedure was car-
ried out within 3 hours after admission to the hospital in
cases of acute arterial ischemia and within 12 hours in
venous cases, if no signiﬁcant venous ischemia or life-
threatening conditions were present. An introducer
sheath was placed, and the thrombus aspirates were
obtained using 6-F angio catheters from the proximal
parts of the arteries or grafts and usually distally in the
cases of deep venous thrombosis before initiation of
thrombolysis and placed into Eppendorf tubes. Control
blood samples were taken through the introducer
sheaths before the thrombus aspiration took place and
stored in similar tubes. The specimens were frozen
at 80C after collection. DNA from the samples was
extracted using a commercial QIAmp DNA Mini Kit
(Qiagen Ltd, Calif) according to the instructions provided.
Blood and whole collected thrombus aspirates were then
analyzed using the real-time quantitative polymerase
chain reaction (qPCR). The risk for contamination was
reduced to minimal as the specimen handling was
performed aseptically throughout the whole process.
Real-time qPCR
The presence of bacterial DNA was identiﬁed using
qPCR with ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems, Foster City, Calif) as previ-
ously described12 with Maxima Probe/ROX qPCR Master-
Mix (Thermo Fischer Scientiﬁc, Waltham, Mass). Arterial
thrombus aspirates were compared with arterial control
blood samples, as opposed to venous to venous to
reduce any potential bias caused by sampling from
different sites and, subsequently, bias resulting from
different conditions like ﬂow dynamics and pressure.
The presence of bacterial DNA in thrombus and in con-
trol blood samples were determined by using published
primers and a probe for Streptococcus spp., mainly
S mitis group,12 and universal bacterial primers and a
probe13 using human housekeeping gene, RNAseP
(Applied Biosystems), as a reference gene. Each mea-
surement was performed as duplicates or quadruples
in uncertain cases. The relative amounts of bacterial
DNA in samples were calculated by the comparative
threshold cycle (Ct) method (DDCt, DCtsample  DCtcon-
trol),
14 where the sample was a thrombus aspirate and con-
trol was a blood sample from the same patient. First, the
differences of the Ct values (DCt) between candidate bac-
teria and reference gene measurement (Ct from candi-
date bacteria  Ct from RNAseP) for each sample were
calculated; then the comparative Ct (DDCt) (DCt from
thrombus  DCt from one patient’s own arterial blood)
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was calculated. The samples were marked bacterial posi-
tive, if 2DDCt $ 2.
Comorbid conditions
Data from patients and ﬁles were collected systemati-
cally upon admission to the hospital by one examiner
(D.V.). The following risk factors from their case records
were included in the analysis: age, sex, diabetes mellitus,
dyslipidemia, hypertension, coronary heart disease, cere-
brovascular disease, pulmonary diseases, renal insufﬁ-
ciency, history of previous arterial interventions
(>1 month old), heart rhythm disorders, heart failure,
smoking within 5 years, and duration of symptoms. The
diagnoses for each of the diseases were cross-checked
with the patient and/or considered positive if they had
been established previously at the hospital or mentioned
in the referral, or if the patient was on an appropriate
medication.
Data analysis
Statistical analyses were carried out using the SPSS
Statistics (SPSS, Chicago, Ill) software package. Fisher’s
exact test and Pearson c2 tests were used for nominal
parameters. Independent samples Mann-Whitney U test
was used to analyze the association of continuous
parameters (age, symptoms duration) with the presence
of bacterial DNA. Statistical signiﬁcancewas set at P# .05.
RESULTS
Altogether, 42 thrombus and control blood samples
accordingly were collected and analyzed. There were
24 specimens from men (57.1%). Of the 42 thrombus as-
pirates obtained, three were excluded from further statis-
tical analysis for associations of total bacterial DNA with
various parameters owing to technical failure in sample
processing. In two of those samples, the evaluation of
S mitis group DNA was impossible for the same reason.
The samples were considered positive, if the amount of
bacterial DNA in the thrombus aspirates was twofold or
greater15 in comparison with control blood samples.
Thus, for the total bacterial DNA the mean fold differ-
ence was 12.1 (median, 7.1), whereas the differences for
S mitis group DNA were a mean of 29.1 and a median
of 5.2-fold (Fig).
Distributions of comorbidities and other variables are
presented in the Table. The total prevalence of any bacte-
rial DNA in successfully processed samples of thrombus
aspirates was 64.1% (n ¼ 25; bacteria not speciﬁed and
include all possible microorganisms). Of the 19 arterial
thrombus aspirates, 11 (57,9 %) were positive for bacterial
Table. Patient characteristics and association of bacterial DNA occurrence with various parameters
Characteristics
All patients
(N ¼ 42)
Positive total bacterial DNA
(n ¼ 25)
Positive S mitis group DNA
(n ¼ 23)
Median age (range), years 70 (38-92) 69 (38-92) 67 (38-92)a
Male gender 24 (57.1) 13 (52.0) 14 (60.9)b,c
Diabetes 12 (28.6) 8 (32.0) 6 (26.1)b,c
Dyslipidemia 19 (45.2) 12 (48.0) 11 (47.8)b,c
Arterial hypertension 31 (73.8) 21 (84.0) 17 (73.9)b,c
Coronary heart disease 6 (14.3) 4 (16.0) 4 (17.4)b,c
Cerebrovascular disease 4 (9.5) 3 (12.0) 3 (13.0)b,c
Pulmonary disease 10 (23.8) 7 (28.0) 7 (30.4)b,c
Renal insufﬁciency 4 (9.5) 3 (12.0) 3 (13.0)b,c
Previous arterial procedure 19 (45.2) 14 (56.0) 14 (60.9)b,c,d
Arrhythmias 10 (23.8) 4 (16.0) 4 (17.4)b,c
Heart failure 4 (9.5) 2 (8.0) 2 (8.7)b,c
Smoking within 5 years 19 (45.2) 14 (56.0) 12 (52.2)b,c
Type of thrombus aspirate
Vein 11 (26.2) 5 (20.0) 5 (21.7)b,c
Artery 19 (45.2) 11 (44.0) 10 (43.5)b,c
Arterial bypass graft 12 (28.6) 9 (36.0) 8 (34.8)b,c
Autologous vein 3 (7.1) 2 (8.0) 2 (8.7)b,c
Prosthesis 9 (21.4) 7 (28.0) 6 (26.1)b,c
Median symptom duration (range), days 7 (1-30) 7 (1-30) 7 (1-30)a
Data are presented as number (%) unless otherwise indicated.
aMann-Whitney U test.
bFisher’s exact test.
cPearson c2.
dP < .05.
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DNA. Bacterial genomeswere found in 9 of 12 bypass graft
thrombosis specimens (75%) with 7 of 9 prosthetic graft
thrombi (77.8%) being positive. Of the deep vein
thrombus aspirates, 5 of 11 (45.5%) contained bacterial ge-
nomes. Themajority, 20 of 25 bacterial DNA positive cases
(80%), contained DNA from S mitis group. There were no
previous venous interventions in the group examined;
however, previous arterial intervention was found to be
associated with the occurrence of S mitis group, whereas
the associations of bacterial DNA presence with other pa-
rameters were not signiﬁcant (Table).
DISCUSSION
To the extent of our knowledge, this is the ﬁrst study to
demonstrate the presence of bacterial DNA in thrombus
aspirates of patients with symptomatic lower limb
arterial and acute deep venous thrombosis. We also
demonstrated that 80% of bacterial DNA was from the
S mitis group. Our ﬁndings are in accordance with the
results of bacterial DNA analysis of thrombus aspirates
from the coronary arteries of patients with myocardial
infarction and specimens taken from the intracranial
aneurysms.4,6 This study has also shown that previous
arterial manipulations were signiﬁcantly associated with
the presence of S mitis group DNA.
There has been growing evidence in favor of the role of
oral bacteria in the pathogenesis of atherosclerosis.16
Furthermore, S mitis group, as a representative of oral
bacterial species, seems to have an exceptional ability
to bind platelets causing their aggregation.2,3,17,18 At
the same time, bacteria from this group can adhere to
an endothelial surface creating inﬂammatory and
thrombogenic bioﬁlms that allow other bacteria to atta-
ch as well,19 which, in turn, can potentially escalate the
effect of platelet aggregation. In contrast, there is evi-
dence that the platelets themselves play an important
role in the response to infection by binding to the bac-
terial surface, aggregating and secreting antibacterial
peptides and cytokines to recruit immune cells to elim-
inate (phagocytize) the bacterial agents.18,20,21 Oral bac-
teria can access the bloodstream through the
endothelial lesions in the oral cavity and as a result of
dental infections. Thus, a signiﬁcant association be-
tween the presence of a periapical dental abscess and
S mitis group DNA in the coronary thrombus aspirates
in patients with acute myocardial infarction was estab-
lished.4 Bacteremia may, however, occur not only in
periodontitis patients, but in individuals with no signiﬁ-
cant periodontal disease as well.22 It was demonstrated
that dental procedures, tooth brushing, and even gum
chewing may produce bacteremias of orally derived mi-
croorganisms.23,24 Odontogenic bacteria have, there-
fore, been found on heart valves, endocardium, or
atherosclerotic plaques.18
These mechanisms seem logical in the situations where
thrombotic events occur in the arteries, where we deal
with the overt disruption of the intima owing to athero-
sclerotic plaques or previous arterial procedures. Thus, a
prosthetic bypass graft, being a foreign surface, is a
preferred target for bacterial adherence,25 despite the
absence of a natural endothelial layer, which is
substituted by neointima. Neoendothelialization of
polytetraﬂuoroethylene grafts includes phases of platelet
aggregation and ﬁbrin network formation.26 Bacteria, in
turn, are known to have an ability to adhere to platelets
and ﬁbrin.27 Furthermore, in this work the thrombus
samples were obtained exactly from the proximal parts
of the grafts near the anastomosis area, which usually
contains natural intima that could provide bacteria
with a suitable adherence surface.
The role of bacterial presence in thrombus formation is
not understood completely. Frequent bacteremia events
may result in an accumulation of pathogens in athero-
sclerotic plaques with a development of a chronic
low-grade inﬂammation.4 Rupture of a plaque inhabited
by microorganisms with a platelet binding potential
could, in turn, lead to a clot formation.
Deep venous thrombosis may have similar characteris-
tics, even though the overt mechanical endothelial
disruption is usually absent. According to the postulates
of Virchow’s triad,28 slow velocity in the venous ﬂow may
be one of the reasons of thrombosis, which is described
in a mathematical model performed by Elizondo
et al.29 Deep venous thrombosis of the lower limb usually
occurs in the area of a valve, where the ﬂow separation
takes place and results in recirculation and interaction
of blood cells.30 It is likely that the presence of bacteria
in a slow-ﬂow, semi-isolated venous segment would
probably induce platelet activation with their aggrega-
tion, thus, possibly, playing a role in subsequent
thrombosis. Another route for bacteria to enter athero-
sclerotic plaques or larger vein walls during a bacteremia
of any origin could be vasa vasorum, which surround
vascular structures from the adventitial side.
Fig. Relative amounts of bacterial DNA in patients’
thrombus aspirates. N-fold difference (log10) compared
with the subject’s own peripheral blood. The horizontal line
shows the bacterial positivity level (2-fold difference). Col-
umn 1: Total Bacterial DNA. Column 2: S mitis group DNA.
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Possible limitations of this study include the fact that it
reports the presence of bacterial DNA in the examined
samples, but it does not reveal the presence of living mi-
croorganisms and/or their impact on blood clotting.
Culturing and staining, often used to detect the bacterial
species, in our study, unfortunately, had limited potential;
thus, qPCR was used instead. Culturing has a very low
sensitivity, from 103 to 104 of vital bacteria are required
to form a culture.31 Cultivating anaerobic species is
evenmore complicated, and themicroorganisms related
to the periodontal disease, in turn, are predominantly
anaerobic.31 Previously performed studies32,33 have
demonstrated PCR methods in detecting bacterial signs
to be more accurate, time consuming, and cost effective
in comparison with cultures. Furthermore, based on our
previous experience with staining and electron micro-
scopy, revealing whole bacterial structures in the clot
aspirates was not always deﬁnite,4 because bacteria or
bacterial bioﬁlms, if present, could mainly reside on the
endothelial or plaque surfaces and, thus, the distinctly
increased amounts of bacterial DNA in the thrombus
are, possibly, those “on-site” phagocytized bacterial com-
ponents from the bioﬁlms.
It is clear that the presence of bacterial DNA in
thrombus aspirates can also occur if the binding of plate-
lets and bacteria, alternatively, takes place somewhere
else within the blood stream before a thrombus adheres
to an endothelial surface. Besides adhesion, aggregation
of platelets and formation of a clot on an endothelial
surface may attract inﬂammatory cells with elsewhere
phagocytized bacterial DNA fragments. However, a multi-
fold difference in the amounts of bacterial DNA found in
thrombus aspirates suggests their possible role in the
pathogenesis of thrombosis. Nonetheless, how signiﬁcant
this role is remains to be studied by additional methods.
Another weakness of this study is its relatively small
number of cases, which prevents us from performing
further subgroup analysis.
In conclusion, our study is among the ﬁrst to identify the
DNA of themicroorganisms of the oral cavity in the blood
clots of the lower limb vessels. We suppose that species
like S mitis group could be associated with the incidence
of arterial and, possibly, lower limb deep venous throm-
bosis by means of initiation of inﬂammation in the vessel
wall leading to plaque or endothelial alterations that
may eventually result in thrombotic occlusions. The role
of bacteria in venous thrombosis is yet to be studied
but, apparently, inﬂammation might play a key role.
The results of the study are interesting but, nonetheless,
should be interpreted with caution as additional studies
will be needed to reach the ﬁnal conclusion.
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Survival of Patients and Treatment-Related
Outcome After Intra-Arterial Thrombolysis
for Acute Lower Limb Ischemia
Damir Vakhitov,1 Niku Oksala,1,2,3 Eva Saarinen,1 Karim Vakhitov,4 Juha-Pekka Salenius,1
and Velipekka Suominen,1 Tampere, Finland and Saint Petersburg, Russia
Background: The aim of this study is to evaluate the long-term survival and treatment-related
outcome in patients treated with intra-arterial thrombolysis for acute lower limb ischemia.
Methods: The studywas based on a prospective vascular databasewith retrospectively obtained
supplementary information from the patients’ ﬁles. Additionally, data on the patients’ date and
causeof deathwereobtained fromStatisticsFinland.A total of 155patientswith symptomsor signs
of category IeIIa acute lower limb ischemia and angiographic evidence of native artery or bypass
graft thromboembolic eventswere treatedwith intra-arterial catheter-directed thrombolysis (CDT).
Patients with severe ischemic stages at admission or those with contraindications for thrombolysis
(n ¼ 185) were treated with conventional surgical modalities and excluded from further analysis.
Results: The mean age of the patients at admission was 73 years (95% conﬁdence interval
70.1e74.6). For descriptive purposes, age quartiles were used (64, 65e74, 75e82.5, 83).
The mean follow-up time was 126.3 months. The primary patency rates of native arteries/bypass
grafts were 59.8%/31.7%, 35.4%/17.1%, and 18.7%/15.2% at 1, 5, and 10 years, respectively
(P ¼ 0.01). Correspondingly, the respective secondary patency rates were 65.2%/55.6%,
46.7%/39.8%, and 22.8%/30.5% (P ¼ 0.88). A total of 190 additional procedures on 122 patients
were required to preserve the patency after hospital discharge. At 1 year the cumulative survival
was 78%, at 5 years 56%, and at 10 years 29%. The most common cause of death was cardio-
vascular (68.5%), predominantly presented by an acute coronary syndrome, while 9.6% died of
cancer, 6.8% of pulmonary diseases, 8.2% of cerebrovascular causes, and 19.2% owing to
trauma and other reasons. Atrial ﬁbrillation (hazards ratio [HR] 2.31) and age over 83 years
(HR 5.23 per age category) were signiﬁcantly and independently associated with poorer cumu-
lative post-procedural survival. Bypass graft thrombosis was associated with an increase in ma-
jor amputations after CDT (HR 14.77). However, the presence of synthetic bypass grafts had a
protective inﬂuence on limb salvage (HR 0.086). A total of 39 (25.2%) major amputations were
performed during the follow-up period. Age over 75 years was the only signiﬁcant and indepen-
dent factor to negatively impact on amputation-free survival (HR 2.01), which was 24% at
10 years.
Conclusions: The long-term patency after CDT is unfavorable, and additional procedures are
needed to preserve adequate distal perfusion. Approximately 30% of the patients are alive at
10 years after the initial CDT. Increasing age and atrial ﬁbrillation have a negative effect on
the patients’ survival.
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INTRODUCTION
Intra-arterial thrombolysis for the treatment of
lower limb thromboembolic events was introduced
over 2 decades ago and has been routinely used
ever since. The procedure has been shown to be
safe and effective.1e6 However, almost 40% of the
treated patients develop irreversible ischemic
changes, which require major amputations within
the ﬁrst month if the initial thrombolytic therapy
fails.5
Some studies have analyzed the role of comorbid-
ities as well as other factors on the short- and
long-term outcome after thrombolysis3,4,7e9 and
conventional surgical treatment modalities.3,9,10
Nonetheless, the majority of the works assessing
endovascular treatment outcomes focus on
amputation-free survival as their end point and pre-
sent only short- or mid-term results. The studies
differ in cohort sizes, end points, and the statistical
methods used. It is notable that many analyses
reveal advanced age as an independent factor asso-
ciated with mortality.3,4,6,8,9 The presence of other
factors varies and is not consistent. In a large study
by Earnshaw et al.,3 factors that were shown to be
associated with poor post-procedural survival
included female sex, increasing age, native vessel
occlusion, and occlusions of embolic origin. Other
investigators, in turn, found renal insufﬁciency,
ischemic heart disease, cerebrovascular disease,
and the presence of a foot ulcer to be independently
associated with death during the follow-up.7 The
role of atrial ﬁbrillation (AF) in post-thrombolytic
survival is undeﬁned, and the data available on
this issue are scarce.
Patients with acute limb ischemia often have
multiple comorbidities that can affect the prognosis
negatively despite successfully performed lytic ther-
apy.3 Furthermore, acute lower limb ischemia
(ALLI) could indicate the start of a cascade leading
to the end of life, perhaps suggesting a different
approach or, sometimes, palliative care instead.11
To the extent of our knowledge, the data avail-
able concerning the long-term outcomes of CDT
are scarce. Therefore, the aim of this study is to
assess the long-term patency, the need for major
amputations, survival, as well as factors possibly
affecting the outcomes.
MATERIALS AND METHODS
Patients
A total of 340 patients were referred to Tampere
University Hospital (TAUH), Tampere, Finland, for
ALLI between March 2003 and December 2014. Pa-
tients with symptoms or signs of category IeIIa
ALLI12 and angiographic evidence of bypass graft
or native arterial thrombosis were treated with
intra-arterial catheter-directed thrombolysis (CDT)
with alteplase (Actilyse; Boehringer Ingelheim,
Ingelheim, Germany) and included in the study
group (n ¼ 155). This group comprised all the pa-
tients initially treated with CDT. Patients with con-
traindications for thrombolytic therapy, those in
whom an endovascular procedure was unavailable
for various reasons, as well as patients with severe
stages of ischemia at admission (n ¼ 185) were
treated using conventional surgical modalities.
Owing to heterogeneity, these patients were
excluded from further analysis.
Data Collection
The study was based on the local vascular database
registry where the patient-related information had
been entered prospectively. The data were cross-
checked with the case records and, if needed, the
authors (D.V. and E.S.) obtained additional infor-
mation from the patients’ case records retrospec-
tively. The diagnosis for each disease was
considered positive if it had preexisted in the pa-
tient’s hospital records, if it had been mentioned in
the referral, or if the patient was on appropriate
medication. The data on the patients’ causes and
dates of death were obtained from Statistics Finland.
The data on amputations performed after the
treatment for ALLI were collected from the vascular
database registry and the patients’ electronic case re-
cords. Only major amputations above the foot level
were analyzed.
The Ethics Committee of TAUH approved the
study (ethical and other patient’s data-related is-
sues). Informed consent from the patients was not
required.
Study End Points
The primary end points were the primary, assisted
primary, and secondary patencies, in addition to
the major amputation rate as well as the cumulative
and amputation-free survival rates together with
the causes of death in patients initially treated
with thrombolysis. The secondary objective was to
evaluate the factors associated with a poor post-
procedural outcome.
Deﬁnition of Patency
The deﬁnition of patency was based on the guide-
lines of Rutherford et al.12 Patency was assessed
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using objective clinical examinationmethods (ultra-
sound and/or angiography or ankleebrachial index
measurement along with a clinical examination).
These data were documented in the patients’ history
and partly also in the vascular registry.
Additional endovascular or minor open surgical
procedures were performed in a number of patients
upon the completion of thrombolysis in order to
obtain sufﬁcient distal perfusion. The endovascular
procedures included balloon dilatations and stent-
ings. The minor surgical procedures comprised end-
arterectomies, open angioplasties, and/or short-
segment jump bypasses. The need for such addi-
tional procedures within the same hospital stay after
thrombus dissolution with CDT was still deﬁned as
primary patency.
Statistical Analysis
Kaplan-Meier survival analysis was used to estimate
the patency, survival, and amputation-free survival.
Standard error of <10% was considered reliable.
Cox regression proportional hazards analysis was
used to study the effect of different factors on sur-
vival. The parameters were ﬁrst tested in the
univariable model, and signiﬁcant parameters
(P < 0.05) were included in the multivariable anal-
ysis. The factors were tested for proportional hazards
assumption with a log-minus-log plot, and it was
met for all the factors included in the multivariable
model. Age was evaluated as a continuous param-
eter. For descriptive purposes, the age parameter
was divided into age quartiles (64, 65e74, 75e
82.5, 83).
RESULTS
Altogether, 155 consecutive patients (73 men,
47.1%) were included in the study. Of 155 CDTs
performed, 80 patients (51.6%) required additional
manipulations in order to obtain sufﬁcient distal
perfusion upon the completion of the procedure.
Those modalities included 58 percutaneous balloon
dilatations/stentings, 20 minor surgical procedures,
and 2 hybrid procedures. Moreover, 2 fasciotomies
were performed upon the completion of thrombo-
lytic treatment. Major bleeding requiring an early
termination of the CDT, a blood transfusion, and
surgical hemostasis occurred in 4.2% of the cases.
Additionally, 2more patients developed an intracra-
nial hemorrhage and diedwithin days of the proced-
ure (1.3%).
The patients’ characteristics are presented in
Table I. The mean follow-up was 126.3 months
(95% conﬁdence interval [CI] 111.6e141.1). As ex-
pected, themost common cause of deathwas related
to cardiovascular reasons (68.5%), predominantly
presented by an acute coronary syndrome. Other
reasons included cancer (9.6%), cerebrovascular
events (8.2%), pulmonary diseases (6.8%), and
trauma and other causes (19.2%).
Patency
A total of 190 additional procedures on 122 patients
were required to preserve the patency after hospital
discharge within the 10-year period.
The long-term patency rates were generally unfa-
vorable. The primary patency of native arteries was
better than that of bypass grafts at 1, 5, and 10 years
post-procedurally (P¼ 0.01; Fig. 1). The assisted pri-
mary patency of native vessels was also superior to
bypass grafts after the treatment with CDT
(P ¼ 0.03; Fig. 2). The secondary patency did not
differ signiﬁcantly between the native arteries and
bypass grafts (P ¼ 0.88; Fig. 3).
Survival
The cumulative survival analysis of the patients
treated with CDT is demonstrated in Figure 4. The
analysis shows that 78% of patients were alive at 1
year. This number decreased to 56% at 5 years,
whereas 29% of patients were alive at 10 years after
the treatment with CDT.
Univariable analysis. Age over 83 years, heart fail-
ure, diabetes, coronary heart disease, AF, arterial
hypertension, renal insufﬁciency, and a previous
arterial procedure of the ipsilateral limb were signif-
icantly associated with mortality. The presence of a
bypass graft was associated with longer survival.
Multivariable Cox regression analysis. Age over
83 years was signiﬁcantly and independently associ-
ated with poor post-procedural survival (hazards ra-
tio [HR] 5.23 per age category, 95% CI 2.28e12.01,
P ¼ 0.000). Furthermore, AF was signiﬁcantly
and independently associated with poor post-
thrombolytic survival (HR 2.31, 95% CI 1.40e
3.82, P ¼ 0.001).
Major Amputations
A total of 39 (25.2%) major amputations were per-
formed during the follow-up period. Ten of these
(25.6%) were performed within the ﬁrst month
from the procedure, when sufﬁcient distal perfusion
could not be achieved.
Univariable analysis. Factors that predicted major
amputations in patients treated with CDT included
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thrombosis of autologous vein bypasses and the
presence of additional vascular procedures within
6 months after initial lytic therapy.
Multivariable Cox regression analysis. The occur-
rence of graft thrombosis was associated with an
increased risk of major amputation after CDT (HR
14.77, 95% CI 1.86e117.52, P ¼ 0.011). Nonethe-
less, the presence of synthetic bypass grafts seemed
to protect against amputations in patients treated
with CDT (HR 0.086, 95% CI 0.011e0.699,
P ¼ 0.022).
Amputation-free Survival
The amputation-free survival was 66%, 47%, and
24% at 1, 5, and 10 years post-procedurally (Fig. 5).
Univariable analysis. Age over 75 years, female
sex, heart failure, smoking, AF, diabetes, coronary
heart disease, and renal insufﬁciency had an adverse
effect on the survival of patients after CDT. In
contrast, the presence of a synthetic bypass graft
demonstrated a protective effect.
Multivariable Cox regression analysis. Age over
75 years turned out to be signiﬁcant and indepen-
dent as an adverse factor affecting the survival after
CDT (HR 2.01 per age category, 95% CI 1.03e3.92,
P ¼ 0.042). The inﬂuence increased with age, since
the patients aged over 83 years had an HR of 3.84
per age category (95% CI 1.95e7.58, P ¼ 0.000).
DISCUSSION
To the extent of our knowledge, this study is one of
the few to focus on the long-term post-procedural
survival and patency after thrombolysis for acute
lower limb arterial thrombotic events.
The study revealed that the patients died predom-
inantly owing to acute coronary events and cancer.
Furthermore, the study demonstrated that age over
83 years, as well as AF, were signiﬁcantly and inde-
pendently associated with poor post-procedural sur-
vival. Beyond that, the presence of occluded by
pass grafts predicted an increased risk of major
amputation.
Elderly patients presenting with acute lower
limb thromboembolic events have been shown to
have poor survival in the short, medium, and long
term.7e9,13,14 In the recent work by Grip et al.,8
increasing age was a signiﬁcant factor associated
with death within 5 years from thrombolysis
(odds ratio 1.07/year). Our results are in line with
this ﬁnding (HR 5.23 per age category), demon-
strating poorer mid- and long-term post-lytic
survival. This is true particularly for those over
83 years of age. Increasing age is, however, a natu-
ral, nonmodiﬁable factor. It is therefore under-
standable and logical that advanced age has been
found to be associated with mortality after throm-
bolysis in most studies performed in the last
2 decades.2,3,5,7,8
The impact of AF on mortality in patients with
ALLI treated with CDT is not well deﬁned. Further-
more, the data available on this issue are scarce. AF
has been found to be associated with death within
5 years from thrombolysis for ALLI.8 Other recent
studies, however, have not found it to be signiﬁ-
cant.6,7,14 Nonetheless, AF has been revealed to
correlate with an increased risk of cardiovascular
disease.15 In a large study by Benjamin et al.,16 AF
was associated with a 1.5- to 1.9-fold mortality risk
after adjustment for the preexisting cardiovascular
Table I. Patients’ characteristics
Variables
Catheter-directed
thrombolysis
(n ¼ 155)
Age (years), mean 72.7 (12.5)
Female sex, n (%) 82 (52.9)
Heart failure, n (%) 37 (23.9)
Smoking within 5 years 26 (16.8)
Atrial ﬁbrillation, n (%) 70 (45.2)
Diabetes, n (%) 34 (21.9)
Dyslipidemia, n (%) 78 (50.3)
Arterial hypertension, n (%) 120 (77.4)
Coronary heart disease, n (%) 69 (44.5)
Cerebrovascular disease, n (%) 21 (13.5)
Pulmonary disease, n (%) 22 (14.2)
Renal insufﬁciency, n (%) 15 (9.7)
Previous bypass grafting, n (%) 63 (40.6)
Autologous vein graft 17 (11.0)
Synthetic graft 46 (29.7)
Occluded segment, n (%)
Iliac 15 (9.7)
Femoral 11 (7.1)
Femoropopliteal 98 (63.2)
Tibial 31 (20.0)
Lytic therapy + additional
procedure, n (%)
80 (51.6)
Secondary procedure within
6 months, n (%)
23 (14.8)
Severity of acute ischemia
Rutherford I 57 (36.8)
Rutherford IIa 98 (63.2)
Duration of symptoms (days), mean 4.7 (5.5)
Duration of thrombolytic therapy
(days), mean
1.5 (0.5)
Mean presented as values and standard deviation in brackets.
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conditions with which AF was related. AF is known
to have common risk factors and often coexists with
congestive heart failure, whereas the presence of
both conditions identiﬁes patients at an increased
mortality risk.17 In another large study from Swe-
den that included over 200,000 patients with inci-
dental AF, AF was an independent risk factor of
all-cause mortality,18 which supports our ﬁnding.
It is noteworthy that the majority of our patients
with AF received warfarin and the diagnosis
remained present throughout the surveillance
period. It remains debatable whether those patients
could have beneﬁted more if they had been pre-
scribed a different anti-thrombotic therapy. Inter-
estingly, patients with stable atherosclerotic
disease receiving rivaroxaban in addition to aspirin
have been recently reported19 to have a 24% lower
incidence of cardiovascular death, stroke, or
myocardial infarction, but, expectedly, a higher
risk of bleeding than those taking aspirin or rivarox-
aban alone.
Coronary heart disease, cerebrovascular disease,
diabetes, and renal insufﬁciency, despite having
previously been described as signiﬁcant factors
affecting survival7,8 in ALLI patients, did not turn
out to be signiﬁcant in this study. This could be
explained by differences in cohort sizes and the
considerably longer surveillance in our group.
Furthermore, the results may be affected by the
fact that we do not have complete information on
the management of risk factors among these pa-
tients nor on the patients’ commitment to taking
the prescribed medication.
Some authors have shown female sex3 to have a
negative impact on survival after thrombolysis. This
ﬁnding is, however, contradicted by other investiga-
tors6,7,12 and the results of our study as well. In gen-
eral, women tend to live longer even with the same
risk factor proﬁles as men, so we are inclined to
believe that long-term survival after thrombolysis
for ALLI could probably be better among women.
To resolve this question, larger prospective cohorts
would be needed.
Severe stages of ischemia have previously been
shown to have an adverse effect on survival.8,9 In
our institution, we tend to manage patients with se-
vere stages of ischemia surgically.12 Consequently,
these patients were excluded from this study, and
we therefore lack reliable data on the outcome of
these patient groups after CDT. Nonetheless, the
less severe stages analyzed in our cohort did not
signiﬁcantly affect the survival of the patients,
Fig. 1. Primary patency after CDT for native arterial (black curve) or bypass graft ( gray curve) thrombosis. Kaplan-Meier
survival analysis (P ¼ 0.01).
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which is in line with the previously published
data.5,8,9,13
According to our results, the presence of
occluded bypass grafts seemed to increase the risk
for major amputations after CDT. We suppose
that this is true particularly for autologous vein
grafts, since it has been suggested that they develop
endothelium alterations due to ischemia.20 Conse-
quently, this can result in thrombolytic treatment
failure20 or poor graft patency. On the other
hand, patients with distal autologous vein ‘‘by-
passes’’ often present with more advanced athero-
sclerotic changes than those with short proximal
synthetic bypass grafts or those with native arterial
thrombotic events. It is worth noting that the syn-
thetic bypass grafts which, in our work, appeared
to have a protective inﬂuence on limb salvage,
can often be reopened with thrombolysis.5 Un-
doubtedly, obtaining adequate perfusion can help
preserve a viable limb for the time being. Nonethe-
less, the development of a thin prothrombotic layer
in synthetic grafts can affect their patency,5,20
requiring additional endovascular or open
procedures in order to maintain sufﬁcient distal
perfusion. In our cohort, 122 patients underwent
a total of 190 additional procedures within a 10-
year period after the CDT.
The long-term patency after initial CDT was
largely unfavorable. Furthermore, roughly 30%
of the patients treated were alive at 10 years
post-procedurally. Even though the results are
generally in line with the previously reported ﬁn-
dings,7e9,14 the studies are difﬁcult to compare
due to dissimilar end point selection. In our
work, native arteries showed signiﬁcantly better
primary and assisted primary patency rates in com-
parison to bypass grafts after the initial treatment
with CDT. Patients with bypass grafts usually pre-
sent with more advanced stages of atherosclerosis
that consequently predispose them to an inferior
outcome. The secondary patency rates were
decreased in both native arteries and bypass grafts.
There was no signiﬁcant difference between them.
This adverse outcome is supported by the fact that
the long-term amputation-free survival rate was
poor as well. The patients presented were
Fig. 2. Assisted primary patency after CDT for native arterial (black curve) or bypass graft ( gray curve) thrombosis.
Kaplan-Meier survival analysis (P ¼ 0.03).
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predominantly elderly individuals with multiple
comorbidities. It is clear that multiple additional
procedures, the progression of underlying athero-
sclerotic changes, diabetic angiopathy, and the
loss of runoff vessels and collaterals could eventu-
ally result in unfavorable long-term patency rates.
It remains debatable whether initial endovascular
thrombectomy and additional consequent throm-
bolysis could have improved the results.
Our study has some limitations. Althoughmost of
the data were collected prospectively, it did not
include evidence of anti-coagulant treatment for
all the patients included in the study. We do not
believe, however, that it would have brought any
additional and reliable value to our work. The
anti-coagulant used in the majority of cases was
warfarin, which makes it difﬁcult to determine
whether the patient had proper anti-coagulation
status at the time of the thromboembolic event. It
must be emphasized that, although the events
were classiﬁed as thrombotic, embolic events could
have been present as well. A further diagnostic deﬁ-
nition was sometimes impossible and could,
therefore, be misleading especially in regard to sta-
tistical analysis.
Another drawback of our study is the fact that
some missing data were also obtained retrospec-
tively, which, in turn, could increase bias resulting
from miscoding and a lack of clinical information
in the patients’ ﬁles. However, the proportion of
the retrospective data was not considerable, and
we postulate that it did not inﬂuence the results
signiﬁcantly.21 One more limitation of the study is
the inability to perform further subgroup analyses
due to the cohort size.
CONCLUSION
The long-term patency after CDT is unfavorable,
and additional procedures are needed to preserve
adequate distal perfusion. Approximately 30% of
the patients are alive at 10 years after the initial
CDT. Increasing age and AF have a negative effect
on the patients’ survival.
Fig. 3. Secondary patency after CDT for native arterial (black curve) or bypass graft ( gray curve) thrombosis. Kaplan-
Meier survival analysis (P ¼ 0.88).
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Fig. 4. Cumulative survival of patients with ALLI after CDT. Kaplan-Meier survival analysis.
Fig. 5. Amputation-free survival of patients with ALLI after CDT. Kaplan-Meier survival analysis.
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Prognostic risk factors for recurrent acute lower limb
ischemia in patients treated with intra-arterial
thrombolysis
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ABSTRACT
Objective: The objective of this study was to assess factors predisposing patients to recurrent acute lower limb ischemia
(RALLI).
Methods: Acute lower limb ischemia patients treated with catheter-directed thrombolysis (CDT) at Tampere University
Hospital and Turku University Hospital between March 2002 and December 2015 were included. The patients’ baseline
demographics, comorbidities, and other characteristics were assessed retrospectively. Signiﬁcant factors revealed by
univariable analysis were tested in a multivariable model for associations with RALLI. A patency analysis was performed,
and the risks of reocclusion were identiﬁed. The limb salvage rates after reocclusion were evaluated.
Results: Altogether, 303 consecutive patients with amean age of 71 years (standard deviation, 11.8 years) were included. Of
them, 159 (52.5%) were men. A total of 164 (54.1%) native arterial and 139 (45.9%) bypass graft occlusions were initially
treated with CDT. On completion of CDT, 204 additional endovascular or conventional surgical procedures on 203 pa-
tients were performed to obtain adequate distal perfusion. During a median follow-up of 40 months (interquartile range,
69 months), 40 (24.4%) cases of RALLI occurred in native arteries and 90 (64.7%) in bypass graft patients (P < .001). In
native arteries, the absence of appropriate anticoagulant and antiplatelet medication was independently associated with
the development of acute reocclusions (hazard ratio, 6.51) in the Cox multivariable regression analysis. The patency rates
were 86.6%, 72.2%, and 68.0% at 1 year, 5 years, and 9 years, respectively. In bypass grafts, worsened tibial runoff (crural
index III: hazard ratio, 2.40) was independently associated with RALLI. The respective patency rates were 60.5%, 34.0%,
and 29.2% for synthetic conduits and 30.8%, 20.5%, and 13.7% for autologous vein grafts at 1 year, 5 years, and 9 years.
Altogether, 38 (29.2%)major amputations were performed on patients with reocclusions. Patients with synthetic conduits
demonstrated superior limb salvage rates after reocclusion in comparison to native arteries or vein grafts (P ¼ .025).
Conclusions: Appropriate post-thrombolytic antiplatelet or anticoagulant treatment after native arterial events is of great
importance, but additional data are needed to improve treatment algorithms. Adequate outﬂow in bypass graft patients is
crucial. Patients with prosthetic bypass grafts have superior limb salvage rates after reocclusion. (J Vasc Surg 2019;-:1-8.)
Keywords: Acute lower limb ischemia; Thrombolysis; Rethrombosis; Reocclusion; Recurrent acute lower limb ischemia
For >20 years, catheter-directed thrombolysis (CDT) has
been used for the treatment of acute lower limb
ischemia. The ﬁrst publications on the use of thromboly-
sis date to the 1950s.1 According to the available
literature, the method was ﬁrst introduced in the United
States, but work on the development of ﬁbrinolysis has
been carried out in other countries as well.2,3
Although the technical success rate of the method
exceeds 70%and the short-termamputation-free survival
rates are acceptable,4-6 the postprocedural outcome is
often inﬂuenced by reocclusions, which results in low
long-term post-thrombolytic patency rates.7,8 As a result,
approximately one-quarter of the treated patients
undergo major amputations at some point, and the
long-term amputation-free survival rates remain
disappointing.7 Despite the introduction of newer throm-
bolytic agents and advanced infusion methods, the
results have not considerably improved9 and in fact are
comparable to those of the urokinase era.8 This suggests
that the development of reocclusions at a later stage
could be associated with either impaired hemorheologic
blood properties due to inadequate postprocedural
antiplatelet and anticoagulant therapy or hemodynamic
changes due to physical reasons or organic failure.
Despite the existence of thrombolysis for decades, the
role of insufﬁcient runoff in postprocedural patency
remains debatable.4,6,10-12 Existing reports on other factors
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that affect reocclusion development are few, and thedata
are also inconsistent.4,6,13,14
To address these issues, this study aimed to identify
speciﬁc patient determinants associated with the throm-
botic or embolic development of recurrent acute lower
limb ischemia (RALLI).
METHODS
Data collection. This is a retrospective study based on a
prospectively maintained vascular registry. The registry
data along with the patients’ ﬁles were retrospectively
assessed by D.V. and E.S. at Tampere University Hospital
(Tays) and by H.H. at Turku University Hospital (TYKS).
The angiograms were initially assessed by the radiolo-
gists and later by D.V. at Tays and H.H. at TYKS.
A total of 303 consecutive patients who presented with
Rutherford category I to IIb15 symptoms and signs of
acute or acute-on-chronic lower limb occlusions of
native arteries or bypass grafts were included in the
study. The patients were treated with intra-arterial
thrombolysis in two tertiary vascular referral centers,
Tays and TYKS, between March 2002 and December
2015. The patients were included in the study on an
intention-to-treat basis.
Patients with a deep, progressive sensorimotor deﬁcit
at admission or contraindications to thrombolysis were
treated with conventional surgical modalities and
excluded from further analysis. The duration of symp-
toms no longer than 30 days was generally accepted as
the maximum time threshold for CDT initiation.
The Ethics Committees of both hospitals approved the
study. No informed consent was required from the
patients.
Thrombolysis protocol and antiplatelet or anticoagu-
lant treatment. The procedures were performed under
local anesthesia either by using a contralateral approach
or, alternatively, through the ipsilateral femoral artery. A
multihole Cragg-McNamara infusion catheter (Med-
tronic, Minneapolis, Minn) was placed in the thrombus,
and recombinant tissue plasminogen activator (Actilyse;
Boehringer Ingelheim, Stockholm, Sweden) was admin-
istered as an initial 4-mg bolus. The treatment continued
with an infusion of 0.5 mg/h lasting for a maximum of
48 hours, with control angiograms taken every 24 (62)
hours. For the patients in whom CDT was begun at the
end of the day, the ﬁrst control angiography study was
performed earlier. The end points of lytic therapy were
complete lysis and ﬂow restoration. Duplex ultrasound
scanning and plain radiography could be used for the
differential diagnosis of residual thrombus during CDT.
The patients remained in either an intensive care unit or
a 24-hour observation ward until the thrombolytic treat-
ment was completed. Blood test results were monitored
at least twice daily (complete blood count and potas-
sium, sodium, creatinine, creatine kinase, and myoglobin
levels). Additional tests were performed as necessary.
Fibrinogen levels were not routinely monitored.
Necessary endovascular (percutaneous transluminal
angioplasty [PTA] or stenting) or conventional surgical
procedures (eg, endarterectomy, patch plasty, short-
segment jump bypass) were performed on completion
of thrombolysis to restore patency of a vessel or bypass
graft and to achieve adequate distal perfusion.
Heparin was not infused through the sheath. The low-
molecular-weight heparin enoxaparin sodium (Klexane;
Sanoﬁ-Aventis, Maisons-Alfort, France) 40 mg or
dalteparin sodium (Fragmin; Pﬁzer, Puurs, Belgium)
5000 IU was administered subcutaneously twice daily
instead. Treatment duration with low-molecular-weight
heparin ranged from several days to a maximum of
several weeks (data not shown) and depended on the
patient’s level of physical activity and the need for
continuous oral anticoagulant therapy. Aspirin, 100 mg
daily, was administered to the patients with underlying
atherosclerotic changes that had possibly led to throm-
botic occlusions. Clopidogrel, 75 mg daily, or its combi-
nation with aspirin was administered postprocedurally
for a minimum of 1 month to those who underwent
PTA of the femoropopliteal segment. Treatment dura-
tion was extended to a minimum of 3 months after
PTA or prosthetic bypass grafting involving a tibial
segment. Warfarin or novel analogues were predomi-
nantly administered for varying periods or permanently
in patients with cardiac thrombus, hypercoagulable
state, atrial ﬁbrillation, and occlusions of unknown
origin. In bypass graft patients, severely impaired
outﬂow (crural index III and IV) could become an indica-
tion for long-term anticoagulation. In such cases, the
decision was made on an individual basis. Combinations
of these medications were also prescribed in
selected cases.
ARTICLE HIGHLIGHTS
d Type of Research: Two-center retrospective study of
prospectively collected registry data
d Key Findings: Recurrent acute ischemia in 303
patients was associated with the absence of antico-
agulant or antiplatelet treatment in native arteries
and poor runoff in bypass grafts. Limb salvage rates
after reocclusion were superior in patients with syn-
thetic grafts.
d Take Home Message: Adequate anticoagulant or an-
tiplatelet treatment and sufﬁcient outﬂow are
important determinants of primary patency of revas-
cularizations for acute ischemia. Autologous vein
graft rethrombosis is associated with a higher risk
of amputations in comparison with prosthetic
conduits.
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Follow-up and reocclusions. The follow-up was deter-
mined as the period between the primary treatment
with CDT and the date of study completion or the date of
major amputation or death if either of these occurred
earlier. Hereafter, the term reocclusion is used to refer to
an acute reocclusion of lower limb arteries or bypass
grafts that is of thrombotic or embolic origin. Thrombo-
embolic events of the same vascular segment and deﬁ-
nitely of the same vessel or bypass graft were considered.
The patients were observed for varying periods. Most
patients underwent the ﬁrst routine follow-up visit at
1 month postprocedurally. Subsequent follow-up visits
were scheduled at different time intervals until the pa-
tients did not require additional manipulations and
there were no symptoms and signs of critical limb
ischemia. In further post-thrombolytic follow-up, native
arterial and proximal bypass graft patients (above-knee)
underwent physical examinations in their regional pri-
mary health care centers once a year or more frequently.
Ultrasound and ankle-brachial index (ABI) measure-
ments were performed on symptomatic patients.
Below-knee bypass graft patients underwent hospital
follow-up biannually. The visits routinely included phys-
ical examinations, ABI, toe pressure measurements, and
ultrasound. Additional elective, urgent, and emergency
follow-up visits and admissions were arranged on the ba-
sis of the clinical situation, and the need for angiography
was assessed.
Deﬁnition of the crural index. Outﬂow sufﬁciency after
initial CDT was assessed by means of a crural index.16,17 A
previous study had suggested the method as an indica-
tor of survival in patients with symptomatic peripheral
artery disease.15 A high index was shown to be associated
with poor amputation-free survival.16 For this study, the
method was chosen because of the simplicity of tibial
runoff measurement.
Each tibial vessel is given a score, as follows: 0, no
detectable occlusion or minor stenosis; 1, total occlusion
of <5 cm; 2, total occlusion of <10 cm; 3, occlusion
of <15 cm; and 4, occlusion of >15 cm. The crural index
is the sum of these scores for all three tibial vessels. If
the sum is 0, the index is 0; for sums of 1 to 3, the index
is I; for sums of 4 to 6, the index is II; for sums of 7 to 9,
the index is III; and for sums of 10 to 12, the index is IV.16
End points. The end points of the study were reocclu-
sion events after initial treatment with CDT and limb
salvage. The factors affecting the development of reoc-
clusion after CDT were established separately for the sub-
groups of patients with native arterial occlusions and of
patients with bypass grafts.
Statistical analysis. The statistical analyses were per-
formed with IBM SPSS Statistics for Macintosh, version
25.0 (IBM Corp, Armonk, NY). The c2 test was used to
compare categorical variables; the independent samples
t-test and Mann-Whitney U test were applied for
continuous variables. Bypass graft patients were assessed
as an entity in the risk factor analysis because of the
relatively small number of vein conduit patients. Uni-
variable analysis was performed using a Cox proportional
hazards model to determine possible risk factors for
reocclusion. The parameters were assessed for a pro-
portional hazards assumption with a log-minus-log plot.
It was met for all factors tested. The signiﬁcant parame-
ters demonstrating a P value of <.05 were then included
in the Cox multivariable backward stepwise regression
model. The probability for a stepwise model was set to
.05 for entry and to .10 for removal. Kaplan-Meier survival
analysis was used to assess the primary patency
(freedom from reocclusion) and limb salvage rates of
patients with native arterial and bypass graft reocclusion
events. A standard error of <10% was considered reliable.
RESULTS
Altogether, 303 (152 from TYKS and 151 from Tays)
consecutive patients treated with CDT for RALLI were
included in the study. The majority of the parameter dis-
tributions were similar among the patients of both hos-
pitals. The patients’ characteristics are presented in
Table I.
Thrombolytic therapy was continued for a median of
1 day (interquartile range [IQR], 1 day; mean, 1.3 days
[standard deviation, 0.5 day]). There were no statistically
signiﬁcant treatment duration differences between
thrombosis and embolism or native arteries and bypass
grafts. The median amount of recombinant tissue plas-
minogen activator per treatment was 17.0 mg (IQR,
11.0 mg; mean, 20.1 mg [standard deviation, 5.8 mg]).
CDT as a monotherapy was sufﬁcient in 100 cases. One
patient underwent endovascular mechanical thrombec-
tomy with a Rotarex system (Straub Medical AG, Wangs,
Switzerland) as an adjunct. A total of 204 additional pro-
cedures in 203 patients were required on the completion
of thrombolysis to restore adequate distal perfusion. Of
them, 112 procedures were performed after native arterial
occlusions and 92 after bypass graft events. The majority
of these (183) were PTAs and stent applications; addi-
tional endarterectomies were needed in 13 cases. Eight
bypass or jump bypass reconstructions were performed
to obtain sufﬁcient distal circulation in the limb. These
numbers include 45 cases of partially completed throm-
bolysis and additional open or endoluminal aspiration
thrombectomies for the progression of ischemia during
lytic therapy. A failure to dissolve the thrombus in
occluded native arteries, bypass conduits, or runoff
vessels resulted in four (1.3%) early major amputations
performed within 10 days from the initial CDT.
A total of 18 (5.9%) patients developed bleeding compli-
cations at the access site and required termination of
thrombolysis and blood transfusion. In addition, four pa-
tients (1.3%) developed intracranial bleeding, and two
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(0.7%) of them died. A compartment syndrome was
revealed in four (1.3%) cases. Lysis had to be terminated,
and adjunct open thrombectomy and fasciotomy were
performed on one of these patients. The three other pa-
tients did not require thrombolysis termination because
the compartment syndrome developed either right after
the treatment or at the end of it. The presence of proce-
dural complications had no statistically signiﬁcant effect
on the long-term outcome.
A total of 130 (42.9%) acute reocclusion events of throm-
boembolic origin were identiﬁed during a median study
period of 40 months (IQR, 69 months). Reocclusion
events predominantly occurred in patients with bypass
grafts. The patients with native arterial events were older
and more likely to have a history of chronic renal insufﬁ-
ciency, atrial ﬁbrillation, and heart failure. No statistically
signiﬁcant differences were identiﬁed between the
groups in patient distribution over the anatomic
Table I. Patients’ characteristics
Variables
Native arteries
(n ¼ 164)
Bypass grafts
(n ¼ 139)
Total
(N ¼ 303)
Baseline
demographics
Sex, malea 81 (49.4) 78 (56.1) 159 (52.3)
Age, years, meanb 74 (12.4) 68 (10.2) 71 (11.8)
Comorbiditiesa
Diabetes 44 (26.8) 30 (21.6) 74 (24.4)
Dyslipidemia 55 (33.5) 61 (43.9) 116 (38.3)
Arterial
hypertension
122 (74.4) 101 (72.7) 223 (73.6)
Coronary heart
disease
67 (40.9) 50 (36.0) 117 (38.6)
Cerebrovascular
disease
23 (14.0) 20 (14.4) 43 (14.2)
Pulmonary
insufﬁciency
27 (16.5) 24 (17.3) 51 (16.8)
History of smoking
in last 5 years
34 (20.7) 31 (22.3) 65 (21.5)
Renal insufﬁciency 15 (9.1) 4 (2.9) 19 (6.3)
Atrial ﬁbrillation 77 (47.0) 40 (28.8) 117 (38.6)
Heart failure 43 (26.2) 19 (13.7) 62 (20.5)
Preprocedural data
Duration of
ischemia, days,
medianc
2 (6) 3 (6) 2 (6)
Type of occluded
vessela
Native artery 164 (100) N/A 164 (53.9)
Synthetic conduit N/A 113 (81.3) 113 (37.2)
Autologous vein
graft
N/A 26 (18.7) 26 (8.6)
Ischemia,
Rutherford
categorya
I 30 (18.3) 29 (20.9) 59 (19.5)
IIa 76 (46.3) 54 (38.8) 130 (43.0)
IIb 58 (35.4) 56 (40.3) 114 (37.6)
Proximal anatomic
segment
involveda
Iliac 22 (13.4) 16 (11.5) 38 (12.5)
Femoropopliteal 112 (68.3) 105 (75.5) 217 (71.4)
Tibial 30 (18.3) 18 (12.9) 48 (15.8)
Embolic eventsa
(valid >99%)
64 (39.0) 5 (3.6) 69 (22.8)
Postprocedural data
Additional
procedure on
completion of
CDTa
112 (68.3) 92 (66.2) 204 (67.3)
Medicationa
Aspirin
(valid >99%)
37 (22.6) 20 (14.3) 57 (18.8)
(Continued)
Table I. Continued.
Variables
Native arteries
(n ¼ 164)
Bypass grafts
(n ¼ 139)
Total
(N ¼ 303)
Clopidogrel
(valid >99%)
18 (11.0) 3 (2.1) 21 (6.9)
Dual therapy 27 (16.5) 13 (9.3) 40 (13.2)
Anticoagulant
(valid >95%)
77 (47.0) 65 (46.8) 142 (46.9)
Anticoagulant
and aspirin
10 (6.1) 10 (7.2) 20 (6.6)
Anticoagulant
and clopidogrel
3 (1.8) 5 (3.6) 8 (2.6)
Triple therapy 0 (0) 2 (1.4) 2 (.7)
No medication 11 (6.7) 5 (3.6) 16 (5.3)
Crural indexa
0 14 (8.5) 16 (11.5) 30 (9.9)
I 16 (9.8) 20 (14.4) 36 (11.9)
II 45 (27.4) 34 (24.5) 79 (26.1)
III 61 (37.2) 50 (36.0) 111 (36.7)
IV 28 (17.1) 19 (13.7) 47 (15.5)
ABI, medianc (valid
57%)
0.86 (0.45) 0.93 (0.32) 0.92 (0.39)
TP, mm Hg, medianc
(valid 52%)
70.5 (46.0) 72.0 (57.0) 71.5 (54.0)
Reocclusions
Reocclusion
eventsa
40 (24.4) 90 (64.7) 130 (42.9)
ABI, Ankle-brachial index; CDT, catheter-directed thrombolysis; N/A,
not applicable; TP, toe pressure.
Values are reported as number (%) unless otherwise indicated. Mean
data are presented with standard deviation. Median data are pre-
sented with interquartile range. The parameters with missing data are
presented with valid percentages. Anticoagulant: warfarin or novel
analogues. Dual therapy: aspirin and clopidogrel. Triple therapy: anti-
coagulant, aspirin, and clopidogrel. Statistically signiﬁcant differences
between the variables (P < .05) are presented in bold.
aPearson c2 test.
bIndependent samples t-test.
cMann-Whitney U test.
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segments involved, categories of ischemia, tibial outﬂow
indices, or other objective parameters, including the
postprocedural ABI or toe pressure (Table I).
Reocclusions of native arteries
A total of 40 (24.4%) RALLI events were identiﬁed
among the 164 CDT procedures performed for the treat-
ment of acute native arterial occlusions.
Risk factor analysis. On univariable analysis, female
sex, poor runoff (crural index IV), and absence of antico-
agulant or antiplatelet medication were signiﬁcantly
associated with RALLI.
On multivariable analysis, the absence of anticoagulant
or antiplatelet medication was the only independent fac-
tor that was associated with the development of
reocclusions (Table II). Poor runoff (crural index IV)
demonstrated statistical near signiﬁcance (P ¼ .051).
Bypass graft reocclusions
A total of 90 (64.7%) reocclusion events were identiﬁed
in 139 patients with bypass grafts of the lower limbs.
Risk factor analysis. On univariable analysis, the type of
an occluded bypass graft (vein graft) and impaired tibial
runoff (crural index III and IV) were signiﬁcantly associ-
ated with the development of rethrombosis. The history
of an additional procedure on the completion of CDT
had a protective impact.
On multivariable analysis, worsened runoff (crural index
III) was the only signiﬁcant and independent parameter
found to be associated with the development of
reocclusions (Table II).
Primary patency
Analysis of primary patency in native arterial and bypass
graft patients is presented in Fig 1. Patients treated for
acute native arterial occlusions had signiﬁcantly more
favorable rates than those with bypass conduits (Fig 1).
The autologous vein bypass graft patients were found
to have the lowest patency rates in comparison to the
native arterial or synthetic conduit groups (Fig 1).
The primary patency rate in native arteries after
embolic events was slightly superior to the correspond-
ing rate after thrombotic events, although the difference
was not statistically signiﬁcant. The prevalence of
embolic events in bypass conduits was inadequate to
perform a comparison.
RALLI and limb salvage
A total of 38 (29.2%) major amputations were per-
formed on patients with reocclusions. The majority of
the amputations (20 [52.6%]) were performed within
the ﬁrst month after the RALLI (total median time to
amputation, 0 months; IQR, 15 months).
In patients who developed RALLI, the limb salvage rate
after thrombotic events in native arteries was inferior to
the corresponding rate after embolic events. The differ-
ence was, however, insigniﬁcant. The presence of
reoccluded synthetic conduits was associated with supe-
rior limb salvage in comparison to thrombosis events in
native arterial or autologous vein bypass grafts (Fig 2).
An analysis of the role of embolism on the type of vessel
could not be performed because bypass grafts were
predominantly affected with thrombosis.
DISCUSSION
In this study, we have demonstrated that the acute
reocclusion rate in lower limb arteries and particularly
in bypass grafts was relatively high (42.9%). A failure to
maintain appropriate anticoagulant or antiplatelet med-
ical treatment in native arterial occlusions resulted in
RALLI. In addition, we found impaired tibial outﬂow to
be signiﬁcantly and independently associated with the
development of rethrombosis in patients with conduits.
Our study has some strengths and limitations. Themain
strengths include a relatively large number of cases from
two vascular centers; homogeneous cohorts because of
similar comorbidity distributions among the patients of
both hospitals; and long-term follow-up, wide range of
factor selection, subgroup analyses, and reduced risk of
miscoding and bias because of a limited number of par-
ticipants processing the data. The main drawbacks
include the retrospective design of the study, the pres-
ence of several parameters with missing data, and the
inability to perform a reliable statistical analysis in regard
to the amputation predictors and vein graft occlusions
because of the relatively small number of cases and
the presence of some incomplete data.
In this series, approximately 40% of all native arterial oc-
clusions were of embolic origin and signiﬁcantly associ-
ated with the presence of atrial ﬁbrillation. The absence
of proper anticoagulant or antiplatelet medication was
the only independent predictor of RALLI in multivariable
analysis. Previous studies18,19 had suggested the impor-
tance of anticoagulation in the prevention of RALLI.
This is particularly true for those with cardiac reasons.18
There are, however, few data available to reject or to sup-
port the long-term use of anticoagulants in patients with
no atrial ﬁbrillation or intracardiac thrombus.
The use of antiplatelet medication to prevent recurrent
atherothrombosis is common. The efﬁcacy of aspirin has
been documented in a large number of controlled trials
that included thousands of patients.20 Dual antiplatelet
Table II. Multivariable Cox backward stepwise regression
analysis of the factors associated with reocclusion
Type of affected vessel Hazard ratio (95% CI)
Native arteries
No medication 6.51 (2.35-18.03)**
Bypass grafts
Crural index III 2.40 (1.15-5.00)*
CI, Conﬁdence interval.
Signiﬁcance levels: *P < .05, **P < .001.
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therapy also appears to be beneﬁcial in reducing post-
procedural complications in patients with peripheral ar-
tery disease.21,22 In addition, data from a recent trial
suggested that a combination of rivaroxaban with aspirin
for secondary cardiovascular prevention is even superior
to rivaroxaban alone or aspirin alone.23 In this retrospec-
tive series, we found that the absence of antiplatelet or
anticoagulant medication is independently associated
with the development of reocclusions of native arteries.
However, we could not demonstrate statistically signiﬁ-
cant beneﬁts of the administered antiplatelet or antico-
agulant therapy on the outcome. There could be
several explanations for this phenomenon. First, we are
not convinced of sufﬁcient efﬁcacy of warfarin in some
patients because of the difﬁculties in maintaining inter-
national normalized ratio within the target range.24 Sec-
ond, although the ongoing medication was generally
reported, some data were missing. Furthermore, we are
conﬁdent that there could be patients with suboptimal
adherence in taking prescribed drugs. Thus, the group
of patients with no appropriate medication could actu-
ally be larger and could affect the statistical results.
Although we cannot currently draw any ﬁnal conclusions
on the postprocedural antiplatelet or anticoagulant
treatment algorithms, it is clear that the absence of
such medication could be decisive. Additional informa-
tion from a prospective randomized controlled trial
would be beneﬁcial.
Bypass graft reocclusions occurred signiﬁcantly more
often than native arterial events. According to our data,
impaired tibial outﬂow was found to be an independent
predictor of recurrent graft thrombosis. Little has been
published on the role of insufﬁcient runoff in the patency
of conduits after treatment with CDT, and the existing
reports are difﬁcult to compare because of their heteroge-
neity. Nackman et al14 suggested that the identiﬁcation of
occlusive disease in the outﬂow arteries could predict
conduit failure. Taha et al6 did not ﬁnd the number of
pedal outﬂow vessels to be signiﬁcantly associated with
the loss of patency in a cohort of native arteries and
bypass grafts. On the contrary, a higher preprocedural So-
ciety for Vascular Surgery runoff scorewas associatedwith
a risk of loss of primary patency in the study byByrne et al.4
The primary patency rates were superior in patients with
native arterial events compared with their counterparts
with synthetic or vein grafts. It has been suggested that
“even with adjunctive therapy, vein graft thrombolysis is
unlikely to yield durable patency overall.”14 The primary
Fig 1. Cumulative primary patencydnative arteries, synthetic conduits, and vein grafts. Kaplan-Meier survival
analysis, 95% conﬁdence interval (P < .001). Numbers of limbs at risk and estimated percentage are presented.
6 Vakhitov et al Journal of Vascular Surgery
--- 2019
patency rate after graft or stent occlusion was inferior to
the primary patency rate after arterial thrombosis or
embolus, as reported by Grip et al.25 Furthermore, in our
previous work, we conﬁrmed that the primary and assis-
tedprimary patency rates after treatment of native arterial
events were superior to those after bypass graft throm-
bosis.7 It could be hypothesized that owing to the pres-
ence of vasa vasorum in the arterial wall, the intima is
obviously not exposed to the same degree of ischemic
damage as the vein bypass graft walls are, thus partially
explaining our ﬁndings. Occluded bypass grafts can
generally be reopenedwith CDT, but long-term prognosis
remains inadequate.7,13,26 Endothelial damage in vein
grafts and the development of a thrombogenic layer in
synthetic conduits27 could be a consequence of throm-
bosis, leading to a poor postprocedural outcome.
The limb salvage rate in patients with synthetic conduits
was superior to the rate in individuals with autologous
vein grafts and native arterial recurrent events. The
information to address this issue is limited.4,6,14,25 Unfortu-
nately, none of the mentioned works evaluated limb
salvage from the viewpoint of RALLI. Therefore, the com-
parison of these data to our results would be unjustiﬁed.
Almost all of the patients with native arterial recurrent
events had signs of considerably diminished outﬂow.
Subsequently, the inability to restore sufﬁcient circula-
tion resulted in major amputations. Irreversible ischemic
changes of the endothelium in vein bypass grafts could
expose such conduits to poor patency rates. Further-
more, at our institutions, autologous vein grafts are
commonly used for distal (below-knee) bypass surgery.
Advancing distal peripheral artery disease and an
inability to restore circulation in the limb after graft fail-
ure would obviously also predispose many of these pa-
tients to major amputations. In contrast, synthetic
conduits are often used for the correction of more prox-
imal lesions. Although the patency of reopened conduits
is usually poor, the limb can generally be salvaged by
means of additional surgical procedures (eg, additional
bypass grafting involving more distal segments), thus
explaining our results.
CONCLUSIONS
Appropriate post-thrombolytic antiplatelet or anticoag-
ulant treatment after native arterial events is of great
importance, but additional data are needed to improve
the treatment algorithms. Adequate outﬂow in bypass
graft patients is crucial. Patients with prosthetic bypass
grafts have superior limb salvage rates after reocclusion.
AUTHOR CONTRIBUTIONS
Conception and design: DV, HH, NO, VS
Analysis and interpretation: DV, HH
Data collection: DV, HH, ES
Fig 2. Limb salvage after reocclusiondnative arteries, synthetic conduits, and vein grafts. Kaplan-Meier survival
analysis, 95% conﬁdence interval (P ¼ .025). Number of limbs at risk and estimated percentage are presented. The
vertical dashed line indicates the point from which the number of remaining vein graft cases is small (standard
error >10%).
Journal of Vascular Surgery Vakhitov et al 7
Volume -, Number -
Writing the article: DV
Critical revision of the article: DV, HH, ES, NO, VS
Final approval of the article: DV, HH, ES, NO, VS
Statistical analysis: DV
Obtained funding: DV
Overall responsibility: DV
REFERENCES
1. Fletcher A, Alkjaersig N, Smyrniotis F, Sherry S. The treat-
ment of patients suffering from early myocardial infarction
with massive and prolonged streptokinase therapy. Trans
Assoc Am Physicians 1958;71:287-96.
2. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Köstering H,
Oster H, et al. Acute myocardial infarction: intracoronary
application of nitroglycerin and streptokinase. Clin Cardiol
1979;2:354-63.
3. Chazov EI, Matveeva LS,MazaevAV, SarginKE, SadovskaiaGV,
Ruda MI. [Intracoronary administration of ﬁbrinolysin in
acute myocardial infarct]. Ter Arkh 1976;48:8-19.
4. Byrne RM, Taha AG, Avgerinos E, Marone LK, Makaroun MS,
Chaer RA. Contemporary outcomes of endovascular in-
terventions for acute limb ischemia. J Vasc Surg 2014;59:
988-95.
5. Earnshaw JJ, Whitman B, Foy C. National Audit of Throm-
bolysis for Acute Leg Ischemia (NATALI): clinical factors
associated with early outcome. J Vasc Surg 2004;39:1018-25.
6. Taha AG, Byrne RM, Avgerinos ED, Marone LK, Makaroun MS,
Chaer RA. Comparative effectiveness of endovascular versus
surgical revascularization for acute lower extremity
ischemia. J Vasc Surg 2015;61:147-54.
7. Vakhitov D, Oksala N, Saarinen E, Vakhitov K, Salenius JP,
Suominen V. Survival of patients and treatment-related
outcome after intra-arterial thrombolysis for acute lower
limb ischemia. Ann Vasc Surg 2019;55:251-9.
8. Schrijver AM, de Vries JP, van den Heuvel DA, Moll FL. Long-
term outcomes of catheter-directed thrombolysis for acute
lower extremity occlusions of native arteries and prosthetic
bypass grafts. Ann Vasc Surg 2016;31:134-42.
9. Morrison H. Catheter-directed thrombolysis for acute limb
ischemia. Semin Intervent Radiol 2006;23:258-69.
10. van den Berg JC. Thrombolysis for acute arterial occlusion.
J Vasc Surg 2010;52:512-5.
11. Creager MA, Kaufman JA, Conte MS. Acute limb ischemia.
N Engl J Med 2012;366:2198-206.
12. Acar RD, Sahin M, Kirma C. One of the most urgent vascular
circumstances: acute limb ischemia. SAGE Open Med 2013;1.
2050312113516110.
13. Plate G, Oredsson S, Lanke J. When is thrombolysis for acute
lower limb ischemia worthwhile? Eur J Vasc Endovasc Surg
2009;37:206-12.
14. Nackman G, Walsh D, Fillinger M, Zwolak R, Bech F,
Bettmann M, et al. Thrombolysis of occluded infrainguinal
vein grafts: predictors of outcome. J Vasc Surg 1997;25:
1023-32.
15. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM,
Ahn S, et al. Recommended standards for reports dealing
with lower extremity ischemia: revised version. J Vasc Surg
1997;26:517-38.
16. Wickström JE, Jalkanen JM, Venermo M, Hakovirta HH.
Crural Index and extensive atherosclerosis of crural vessels
are associated with long-term cardiovascular mortality in
patients with symptomatic peripheral artery disease.
Atherosclerosis 2017;264:44-50.
17. Jalkanen JM, Wickström JE, Venermo M, Hakovirta HH. Data
on amputation free survival of patients with lower limb
peripheral artery disease classiﬁed according TASC II classi-
ﬁcation and a new crural index. Data Brief 2016;8:242-6.
18. Forbes TL, DeRose G, Harris KA. Is long-term anticoagulation
after acute thromboembolic limb ischemia always
necessary? Can J Surg 2002;45:337-40.
19. Campbell WB, Ridler BM, Szymanska TH. Two-year follow-up
after acute thromboembolic limb ischaemia: the impor-
tance of anticoagulation. Eur J Vasc Endovasc Surg 2000;19:
169-73.
20. Antiplatelet drugs: Antithrombotic Therapy and Prevention
of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest
2012;141(Suppl):e89S-119S.
21. Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH,
Kashyap VS. A systematic review of the efﬁcacy of aspirin
monotherapy versus other antiplatelet therapy regimens in
peripheral arterial disease. J Vasc Surg 1922;67:1922-32.e6.
22. Katsanos K, Spiliopoulos S, Saha P. Comparative efﬁcacy and
safety of different antiplatelet agents for prevention of major
cardiovascular events and leg amputations in patients with
peripheral arterial disease: a systematic review and network
meta-analysis. PLoS One 2015;10:e0135692.
23. Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS,
Branch KR, et al. Rivaroxaban with or without aspirin in
stable cardiovascular disease. N Engl J Med 2017;377:1319-30.
24. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and
effectiveness of warfarin in Medicare beneﬁciaries with atrial
ﬁbrillation. Stroke 2006;37:1070-4.
25. Grip O, Wanhainen A, Acosta S, Björck M. Long-term
outcome after thrombolysis for acute lower limb ischaemia.
Eur J Vasc Endovasc Surg 2017;53:853-61.
26. Chalmers R. Late results of a prospective study of direct
intra-arterial urokinase infusion for peripheral arterial and
bypass graft occlusions. Cardiovasc Surg 1995;3:293-7.
27. Conrad MF, Shepard AD, Rubinfeld IS, Burke MW,
Nypaver TJ, Reddy DJ, et al. Long-term results of catheter-
directed thrombolysis to treat infrainguinal bypass graft
occlusion: the urokinase era. J Vasc Surg 2003;37:1009-16.
Submitted Mar 18, 2019; accepted Jul 10, 2019.
8 Vakhitov et al Journal of Vascular Surgery
--- 2019


